

FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE  
(REV. 12-2004)TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

11287256

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/525,256

INTERNATIONAL APPLICATION NO.  
PCT/EP03/009496INTERNATIONAL FILING DATE  
27 August 2003PRIORITY DATE CLAIMED  
27 August 2002

TITLE OF INVENTION

PREVENTING OR TREATING EPITHELIAL TISSUE DAMAGE OR HAIR LOSS

APPLICANT(S) FOR DO/EO/US

Moodycliffe et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a submission under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a submission under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected (Article 31).
5. ☐ A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 23 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A power of attorney and/or change of address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
20. ☐ A second copy of the published International Application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).
22. ☒ Express Mail Label No. EV 351 267 195 US
23. ☒ Other items or information:

Copy of Notification of Missing Requirements (2 pages)

Response to Notification of Missing Requirements (2 pages)

Copy of Preliminary Amendment Filed February 22, 2005 (85 pages)

Return Receipt Postcard

Under the Paperwork Reduction Act

no persons are required to respond to a collection of information

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

App. 1 for use through 3/31/2007. OMB 0651-0021  
less it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5) <b>10/525,256</b>		INTERNATIONAL APPLICATION NO. <b>PCT/EP03/009496</b>		ATTORNEY'S DOCKET NUMBER <b>112843-066</b>	
24. The following fees are submitted:				Applicant use	Office use
<input type="checkbox"/> a) Basic national fee ..... \$300.00				\$	\$0.00
<input type="checkbox"/> b) Examination fee ..... \$200.00				\$	\$0.00
<input type="checkbox"/> c) Search fee ..... \$500.00				\$	\$0.00
<b>TOTAL OF ABOVE CALCULATIONS = \$1000.00</b>				\$	\$0.00
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole)	RATE		
- 100 =	/50 =		x \$250.00	\$	\$0.00
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	\$130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	- 20 =	0	x \$50.00	\$	\$0.00
Independent claims	- 3 =	0	x \$200.00	\$	\$0.00
MULTIPLE DEPENDENT CLAIMS (if applicable) <input type="checkbox"/> + \$360.00				\$	\$0.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$	\$130.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	\$0.00
<b>SUBTOTAL =</b>				\$	\$130.00
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	\$0.00
<b>TOTAL NATIONAL FEE =</b>				\$	\$130.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +				\$	\$0.00
<b>TOTAL FEES ENCLOSED =</b>				\$	\$130.00
Amount to be refunded:					\$
Amount to be charged:					\$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$ <b>\$130.00</b> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is _____</p> <p>c. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <b>02-1818</b>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>					
<p><b>NOTE:</b> Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.</p>					
SEND ALL CORRESPONDENCE TO:					
Robert M. Barrett (30,142) Customer No.: 24573				SIGNATURE	
				Robert M. Barrett	
				NAME	
				30,142	
				REGISTRATION NUMBER	

BEST AVAILABLE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Moodycliffe et al.  
Appl. No.: 10/525,256  
Filed: February 22, 2005  
Title: PREVENTING OR TREATING EPITHELIAL TISSUE DAMAGES OR HAIR LOSS  
Art Unit: Unknown  
Examiner: Unknown  
Docket No.: 112843-066

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY EXPRESS MAIL UNDER 37 CFR 1.10

Sir:

I hereby certify that the following documents relating to the above-identified application:

1. Transmittal Letter (2 pages) (duplicate);
2. Response to Notification of Missing Requirements (2 pages);
3. Copy of Notification of Missing Requirements (2 pages);
4. Executed Declaration (3 pages);
5. Copy of Preliminary Amendment filed February 22, 2005 (85 pages);
6. Check in the Amount of \$130.00; and
7. Return Receipt Postcard.

are being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to:

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on September 13, 2005

Respectfully submitted,

BELL, BOYD & LLOYD LLC

Heather Foster

Name of Person Mailing Correspondence



Signature

EV 351 267 195 US

Express Mail Mailing Label Number

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Moodycliffe et al.  
Appl. No.: 10/525,256  
Conf. No.: 3290  
Filed: February 22, 2005  
Title: PREVENTING OR TREATING EPITHELIAL TISSUE DAMAGES OR HAIR  
LOSS  
Art Unit: Unknown  
Examiner: Unknown  
Docket No.: 112843-066

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS**

Sir:

This Response is submitted in response to the Office Action dated July 14, 2005 regarding the above-referenced patent application.



### REMARKS

This is a reply to the Notification of Missing Requirements mailed on July 14, 2005 (a copy of which is attached).

Responsive to the Notice, Applicants hereby respectfully submit a signed declaration. A check in the amount of \$130.00 is enclosed herewith in payment of the late declaration surcharge as set forth in 37 CFR 1.16(f). The Commissioner is hereby authorized to charge any additional fees to Deposit Account number 02-1818.

The Notice also states that additional claim fees of \$860.00 is required including multiple dependent claim fees. Applicants respectfully submit that pursuant to the Preliminary Amendment filed on February 22, 2005 (a copy of which is attached), the claims were amended so as to cancel the multiple dependency of the claims as originally filed. Therefore, Applicants believe no additional claim fees are required.

Applicants respectfully submit that the application is now complete.

To the extent the Patent Office has any questions regarding this matter, please contact the undersigned attorney.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY 

Robert M. Barrett  
Reg. No. 30,142  
Customer No. 24573

Dated: September 13, 2005



## UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/525,256	Angus Moodycliffe	112843-066

INTERNATIONAL APPLICATION NO.	
PCT/EP03/09496	
I.A. FILING DATE	PRIORITY DATE
08/27/2003	08/27/2002

Robert M Barrett  
 Bell Boyd & Lloyd  
 P O Box 1135  
 Chicago, IL 60690-1135

CONFIRMATION NO. 3290  
 371 FORMALITIES LETTER



\*OC000000016512714\*

Date Mailed: 07/14/2005

*Due: 9-14-05*

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 02/22/2005
- Copy of the International Search Report filed on 02/22/2005
- Copy of IPE Report filed on 02/22/2005
- Oath or Declaration filed on 02/22/2005
- U.S. Basic National Fees filed on 02/22/2005
- Substitute Specification filed on 02/22/2005
- Priority Documents filed on 02/22/2005

RECEIVED  
 BELL, BOYD & LLOYD  
 INTELLECTUAL PROPERTY DOCKET

JUL 18 2005

ATTY *hmb*  
 DOCKET # *112843-066*

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Additional claim fees of **\$860** as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
  - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- **\$130** Surcharge for providing the oath or declaration later than 30 months from the priority date (37 CFR 1.492(e)) is required.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$990 for a Large Entity:

- \$130 Late oath or declaration Surcharge.
- Total additional claim fee(s) for this application is \$ 860
  - \$500 for 22 total claims over 20.
  - \$360 for multiple dependent claim surcharge.

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

PATRICIA A BOOKER

Telephone: (703) 308-9140 EXT 204

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/525,256	PCT/EP03/09496	112843-066

FORM PCT/DO/EO/905 (371 Formalities Notice)

**BEST AVAILABLE COPY**

**IN THE UNITED STATES ELECTED/DESIGNATED OFFICE  
OF THE UNITED STATES PATENT AND TRADEMARK OFFICE  
UNDER THE PATENT COOPERATION TREATY**

5    Applicants:            Moodycliffe et al.  
      Intl. Appl. No.:    PCT/EP03/009496  
      Intl. Filing Date:   27 August 2003  
      Title:              PREVENTING OR TREATING EPITHELIAL TISSUE DAMAGE OR  
                             HAIR LOSS  
10   Docket No.:        112843-66  
  
      Mail Stop PCT  
      Commissioner for Patents  
      P.O. Box 1450  
15   Alexandria, VA 22313-1450

**PRELIMINARY AMENDMENT**

      Sir:  
20        Please amend the above-identified International Application before entry into the  
National stage before the U.S. Patent and Trademark Office under 35 U.S.C. §371 as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page  
25   77 of this paper.

**Remarks** begin on page 85 of this paper.

**Amendments to the Specification:**

Please replace the Specification of the present application, including the Abstract, with the following Substitute Specification. A marked-up version of the Substitute Specification and Abstract is attached hereto.

## SPECIFICATION

### TITLE OF THE INVENTION

**“PREVENTING OR TREATING EPITHELIAL TISSUE DAMAGE OR HAIR LOSS”**

5

### BACKGROUND OF THE INVENTION

The present invention pertains to a method for preventing and/or treating epithelial tissue damage, such as is effected by inflammatory reactions, ageing or cancer and/or to prevent and/or treat hair loss. In particular, the present invention relates to substances and/or compositions modifying, in particular blocking endogenous CD<sub>1d</sub> function. According to another aspect the present invention also provides a method for screening for compounds suitable for use in the method and the composition of the present invention.

### SUMMARY OF THE INVENTION

The most prominent epithelial tissue in living beings is the skin, which represents the largest organ in the organism. The system of skin integument, which comprises the epidermis, dermis and the stratum corneum, correlates with those of internal organs and concurrently interacts with the surroundings. Being the interface between the environment and organism itself, the skin is heavily influenced by external factors and also variable parameters of the organism's inner system. The skin's regulative mechanisms need, therefore, always be active to induce systemic changes necessary to maintain normal pathological events concerning skin integument morphology and activities. A great deal of processes assuring the adequate consumption of increased affluence of energetic and plastic substances according to the skin's needs become guarantors of morphological and functional stability of skin structures. So, the state of integuments determines the realization of metabolic processes necessary for skin cell viability and activity leading to the presence of healthy skin peculiarities such as barrier function, elasticity, turgor properties, humidity, pigmentation etc..

During the lifetime of a living being different signs, characteristic of ageing, appear on the skin, with the principal clinical signs being the appearance of fine lines and deep wrinkles which increase or are accentuated with age. Moreover, the skin's complexion is generally

modified and diffuse irritations and occasionally telangiectasias may come into existence on certain areas.

These signs of ageing are even promoted by exposure of the skin to exogenous influences, such as e.g. UV-radiation, pollutants, free radicals or chemical substances.

5        Moderate UV exposure generally causes the well known effects of reddening the skin with an accompanying inflammation reaction, known as erythema. This phenomenon, often referred to as "sunburn", is painful and commonly results in a subsequent peeling of the skin.

10        Moreover, excessive UV-exposure of the skin may also lead to the onset of severe disorders, such as carcinogenesis, the most common tumours being the basal cell carcinoma (BCC), followed by squamous cell carcinoma (SCC), and more rarely malignant melanoma. Apart from damages on the DNA-level also immuno-suppression caused by UV exposure seems to account for both, non-melanoma and melanoma cancer promotion. It is presently acknowledged that photo-induced immuno-suppression permits the initiated tumour cell to evade recognition and rejection by normal immunological mechanisms, to remain latent for extended  
15        periods, and to eventually proliferate into a tumour. This concept concurs with the findings that immuno-compromised patients, whether genetically (xeroderma pigmentosum) or pharmacologically, such as e.g. organ transplant recipients, have a higher incidence of skin cancer as compared to people with a properly functioning immune system.

20        In the art several means have been proposed to prevent destructive effects of environmental factors on epithelial cells, in particular skin epithelial cells.

25        As regards protection to sun radiation "sun blocks" or "sunscreens" have been made available, which are applied to the skin prior to sun exposure. Typically, sunscreen compositions contain chemical agents, such as certain benzophenones, dibenzylmethanes or substituted para-aminobenzoates, i.e. compounds absorbing ultraviolet radiation, so that it cannot penetrate the skin. However, some of the compounds used for this purpose have shown to lack sufficient light stability and may even become toxic over long term application. In addition, they must stay continuously on the surface of the skin at the time of exposure to be effective. However, sunscreens are easily rubbed off or washed off by sweating or swimming and can also be lost by penetration into the skin.

Another means to prevent skin deterioration or ageing, respectively, is to provide compounds scavenging free radicals. In this respect EP 0 761 214 discloses singlet oxygen quenchers comprising aniline derivatives and difurfuryl amine derivatives, which are reported to reduce the oxidative stress to the skin.

5 Yet, all these means and methods are not sufficiently capable to protect the skin from the growing challenge in our environment. To this contributes an increased atmospheric pollution and also social behaviour, according to which sun-tan is associated with health, beauty and status. As a consequence many people expose their skin to sun radiation to acquire a tan in spite of the negative results accompanying such behaviour being well known. This problem even gets  
10 more prominent with the ozone shield covering the earth becoming thinner, resulting in a heavier exposure of living beings to UV radiation.

Consequently there is a need in the art to provide a better protection of the skin to environmental factors, such as stress or sun radiation.

15 Accordingly, an object of the present invention is to obviate the drawbacks of the prior art and to provide such means in order to protect the skin from unfavourable influences encountered in the environment, in particular from oxidative or chemical stress or sun radiation.

This problem has been solved by providing a substance, that is capable to essentially modify, in particular block the endogenous CD1d function in epithelial cells.

20 Additional features and advantages of the present invention are described in, and will be apparent from, the following Detailed Description of the Invention and the figures.

#### BRIEF DESCRIPTION OF THE FIGURES

Fig. 1A. Wild-type mice exhibit skin damage (burning) following exposure to a single dose ( $86\text{mJ/m}^2$ ) of UVB radiation.

25 Fig. 1B. Wild-type mice exhibit skin damage (burning) following exposure to a single dose ( $86\text{mJ/m}^2$ ) of UVB radiation. (Close-up).

Fig. 1C. CD1d knockout mice show no obvious signs of skin damage following exposure to a single dose ( $86\text{mJ/m}^2$ ) of UVB radiation.

30 Fig. 1D. CD1d knockout mice show no obvious signs of skin damage following exposure to a single dose ( $86\text{mJ/m}^2$ ) of UVB radiation. (Close-up).



Fig. 2 Difference in degree of UVB-induced skin damage between wild-type (Right) and CD1d knockout (Left) mice exposed to two doses ( $86\text{mJ/m}^2$ ) of UVB radiation.

Fig. 2A. Damaged (lesions) dorsal skin of wild-type mice exposed to two doses ( $86\text{mJ/m}^2$ ) of UVB radiation (Close-up).

5 Fig. 2B. Undamaged dorsal skin of CD<sub>1d</sub> knockout mice exposed to two doses ( $86\text{mJ/m}^2$ ) of UVB radiation.

Fig. 3. CD<sub>1d</sub> knockout mice exhibit increased epidermal apoptosis in their dorsal epidermis compared to wild-type mice, as measured by TUNEL. Wild-type (A) and CD1d knockout (B) mouse skin not exposed to UV-irradiation. Wild-type (C) and CD<sub>1d</sub> knockout (D) mouse skin 48h after a single exposure ( $86\text{mJ/m}^2$ ) to UV-B radiation.

Fig. 4 a and b are graphs indicating the approximate amount of CD<sub>1d</sub> in different tissues in mice and human.

Fig. 5 shows that CD<sub>1d</sub> protein is expressed in the epidermis of mouse skin 72h following exposure to a single dose ( $430\text{mJ/cm}^2$ ) of UVB radiation;

15 Fig. 6 shows that murine skin CD<sub>1d</sub> gene transcription is regulated following UVB irradiation;

Fig. 7 shows that murine skin CD<sub>1d</sub> gene transcription is regulated following solar simulated light irradiation;

20 Fig. 8 shows that CD<sub>1d</sub> gene transcription in immortalized (DK7) human keratinocytes is regulated following solar UV irradiation;

Fig. 9. shows that COX-2 and TNF-alpha mRNA levels are down-regulated in UVB-irradiated CD<sub>1d</sub> knockout mouse skin.

Figure 10 a and b) show that mouse skin IL-6 and MIP1-alpha protein levels 48h after UVB irradiation are significantly decreased in CD<sub>1d</sub> KO mice.

25 Fig. 11 shows that hydrocortisone suppresses CD<sub>1d</sub> transcription in cells exposed to a chemical stress; and

Fig. 12 shows that CD<sub>1d</sub> is expressed in human hair follicles.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention is essentially based on the finding that CD<sub>1d</sub>, a transmembrane protein expressed by a number of different cells, in particular epithelial cells, modulates a variety of different responses of the cell to stress. As will become evident from the following detailed description of the preferred embodiments, essentially modifying, specifically blocking the endogenous CD<sub>1d</sub> function in cells bearing said membrane molecule allows to prevent the detrimental effects of stress, including ultraviolet radiation-induced skin damage, e.g. as a result of burning, epidermal hyperplasia, mutant p53 accumulation, inflammation, immune suppression and skin ageing. Even more surprising is the finding that when essentially blocking CD<sub>1d</sub> function in epithelial cells induction of cancer in said cells, i.e. basal cell carcinoma, squamous cell carcinoma, malignant melanoma, colon, breast, liver, prostate, kidney, pancreas cancer etc., may be prevented. In addition, it has been surprisingly found that modifying, in particular blocking CD<sub>1d</sub> function influences hair growth and/or development.

CD<sub>1d</sub> as such is a type 1 transmembrane MHC class 1 like protein that non-covalently associates with  $\beta_2$ -microglobulin. The CD<sub>1d</sub> molecule is recognized by a T-cell receptor of natural killer T-cells (NKT) which play a role in immune modulatory and effector reactions. It has been demonstrated that CD<sub>1d</sub> may present lipids to NKT cells for their activation, which notion is supported by the CD<sub>1d</sub> crystal structure having two highly hydrophobic grooves, necessary for presenting hydrophobic molecules such as lipids to the immune system.

In the studies leading to the present invention it has surprisingly been noted that CD<sub>1d</sub> gene transcription in mouse skin is responsive to external stress, such as UV radiation, which finding has been confirmed in human keratinocytes. In addition it has been noted that skin CD<sub>1d</sub> mediates UV-induced skin damage/inflammation by inducing COX-2 and TNF- $\alpha$  gene transcription and also inhibiting UV-induced apoptosis.

Without wishing to be bound to any theory it is currently assumed that one of the endogenous tasks of CD<sub>1d</sub> in living organisms is to directly control normal epithelial cell homeostasis. Normal skin homeostasis is dependent on the critical and fine tuned balance between epidermal differentiation, apoptosis, proliferation and anti-apoptosis of epidermal cells. In the skin, these processes are regulated via lipids, in particular by means of ceramides and

glucosylceramides (sphingolipids). While the nucleated cell layers generate glucosylceramides (GlcCer), the proportions of GlcCer to Cer decrease late in epidermal differentiation, with the Cer content peaking in the stratum corneum acting as extracellular constituents of the epidermal permeability barrier. In addition to their structural properties, ceramides are associated with inhibition of cellular proliferation, induction of cellular differentiation and programmed cell death. In contrast, GlcCer induce cell proliferation and inhibit programmed cell death.

Based on the findings in the present invention, CD<sub>1d</sub> appears to be one of the receptors via which the above mentioned lipids might fulfill their biological task. Specifically, CD<sub>1d</sub> seems to negatively regulate apoptosis. In consequence, in cells under a stress situation, e.g. when exposed to UV-radiation, CD<sub>1d</sub> supports a continued existence of said stressed cells, even when their genetic material is damaged and/or mutated, which damaged cells will contribute to inflammation processes induced and eventually account for the phenomenon of ageing or eventually tumour development.

In blocking and/or modifying endogenous CD<sub>1d</sub> function, apoptosis of cells under stress may be promoted, instead of their survival and propagation, with the effect that cells that have been damaged to a certain extent, particularly at the DNA level, do not have the chance to proliferate and in case disseminate in the body. The cells once dead will then be extinguished by natural processes in the body and be replaced by "healthy" epithelial cells. Likewise, by means of blocking or modifying CD<sub>1d</sub> also an interaction with NKT is substantially prevented or altered, wherein the phenomenon of immune suppression during exposure to UV radiation will be essentially reduced or barred at all. Also, this condition is supposed to assist the organism's immune system to eradicate damaged cells, brought about by exposure to UV.

The substance capable of blocking and/or modifying the CD<sub>1d</sub> transmembrane molecule's activity may be any substance interfering with the endogenous biological function of CD<sub>1d</sub>, and in particular preventing or reducing association of CD<sub>1d</sub> with endogenous or exogenous lipids. The substances are obtainable by a process comprising the steps of (a) exposing epithelial cells to a substance of interest, (b) subjecting the epithelial cells to a stress situation, (c) determining the effect of said stress to said epithelial cells by screening for one or more of the following assays: (i) epithelial hyperplasia (H&E), (ii) epithelial proliferation (BrUd, PCNA), (iii) epithelial apoptosis, (iv) p53 mutation accumulation, (v) quantitative and qualitative assessment

of epithelial lipids, (vi) co-clustering patterns of apoptotic and non-apoptotic cell surface receptors, (vii) production of pro-inflammatory cytokines, (viii) production of immunomodulatory cytokines, (ix) markers of inflammation, (x) anti-apoptotic transcription factor activity (xi) markers of ageing, and (d) comparing the results obtained with a control. Such a control may e.g. be an assay, wherein the cells have been subjected to the same stress situation, wherein, however, no substance to be investigated had been added (negative control). Likewise a control may also be, including a substance with a known positive effect in the assay and determining the difference in effect achieved by the substance investigated and the known substance (positive control).

A substance is considered to be active in the context of this application, in case it prevents the negative effects of stress as detailed according to any of the above assays.

It will be appreciated that CD<sub>1d</sub> activity may be blocked and/or modified by substances acting on the genetic level or at the protein level.

Substances acting on the genetic level are compounds influencing, in particular preventing transcription or translation of the CD<sub>1d</sub> gene, such as polynucleotides anti-sense to at least a part of the CD<sub>1d</sub> gene or the CD<sub>1d</sub>-mRNA.

The terms oligonucleotide and polynucleotide, which are interchangeably used herein, include linear oligomers/polymers of natural or modified monomers or linkages, including desoxyribonucleosides, ribonucleosides,  $\alpha$ -anomeric forms thereof, polyamide nucleic acids, and the like, capable of specifically binding to the target nucleic acid by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, Hoogsteen or reverse Hoogsteen types of base pairing, or the like. Usually the monomers are linked by phosphodiester bonds or analogs thereof to form oligonucleotides ranging in size from a few monomeric units, e.g. 3-5, to several 100 or even thousands of monomeric units.

The (anti-)sense oligo-/polynucleotides may also contain pendent groups or moieties, to enhance specificity, nuclease resistance, delivery, or other property related to efficacy, such as e.g. cholesterol moieties, duplex intercalators such as acridine, poly-L-lysine, "end capping" with one or more nuclease-resistant linkage groups such as phosphorothioate, and the like. The corresponding oligonucleotide may be used for blocking transcription, RNA processing and/or

translation of the mRNA, Consequently, the oligonucleotide may comprise exon, but also intron sequences of the CD<sub>1d</sub>-target gene, as desired.

5 The nucleotide sequence of the human CD<sub>1d</sub> gene or mRNA is obtainable from NCBI (Accession numbers: AP002532 and NM\_001766, respectively). Based on his general knowledge and skill, the skilled person may select at least a portion of the coding region of the CD<sub>1d</sub> gene and design an appropriate anti-sense polynucleotide, that prevents transcription and/or translation of the CD<sub>1d</sub> gene. Likewise, also a part of the non-coding region of the CD<sub>1d</sub> gene may serve as an agent for preventing transcription or reducing the number of transcripts, respectively, of the CD<sub>1d</sub> gene. Here, in particular parts of the promotor region may serve as a  
10 template for preparing an antisense polynucleotide, but likewise transitions regions from introns and exons and vice versa. According to a preferred embodiment such a substance may be an DNA or a cRNA (RNA-interference).

Yet, apart from the CD<sub>1d</sub> gene being the target, also the activity of a number of regulatory molecules which control epithelial homeostasis such as ceramides and/or glucosylceramides,  
15 may be modified such, that they exert the desired effect on the CD<sub>1d</sub> molecule. To this end, the number of the glucosylceramide synthase transcripts may be reduced by designing an polynucleotide antisense to at least a part of the glucosylceramide synthase gene or glucosylceramide synthase mRNA, so that eventually the signal to epithelial cells to proliferate is turned down. The nucleotide sequence of the glucosylceramide synthase gene is disclosed in  
20 Ichikawa et al., PNAS 93 (1996), 4638-4643, which document is incorporated herein by way of reference. Likewise, non coding regions may serve as a template for the antisense polynucleotide, such as the promotor region and/or transitions from introns to exons and vice versa. According to a preferred embodiment such a substance may be a DNA or a cRNA (RNA-interference).

25 Apart from reducing the proliferation signal also the signal driving epithelial cells to apoptosis via the CD<sub>1d</sub> molecule may be enhanced. In this respect the number of corresponding transcripts may be increased, which may be effected by providing a higher number of polynucleotides encoding a sequence comprised by the sphingomyelinase or ceramide synthase gene and/or the sphingomyelinase or ceramide synthase mRNA.

Apart from the genetic level, the biological activity of the CD<sub>1d</sub> molecule may also be modified, in particular blocked at the protein level, in particular by any substance binding to the CD<sub>1d</sub> receptor on or in epithelial cells and blocking the endogenous biological functionality thereof.

5        According to a preferred embodiment the substance capable of modifying, in particular blocking biological CD<sub>1d</sub> function is a polypeptide or a peptide, in particular hydrophobic peptides, more preferably an antibody, or a part thereof, that binds to the CD<sub>1d</sub> receptor and blocks its biological function, such as the interaction with NKT. As parts thereof, in particular mini-antibodies are envisaged lacking the F<sub>c</sub>-part. According to an alternative embodiment the  
10        substance capable of blocking the biological CD<sub>1d</sub> function may also be a soluble CD<sub>1d</sub> receptor, that is, that part of the polypeptide lacking the region, anchoring the polypeptide in the membrane. The soluble CD<sub>1d</sub> receptor will scavenge the in vivo ligands that promote survival of the stressed cells, thus promoting apoptosis. In addition, binding of the natural killer cells to CD<sub>1d</sub> in vivo will be reduced, thus preventing activation of the T-cells and consequently  
15        inflammatory and/or immunosuppressive reactions.

      According to a preferred embodiment the substance capable of blocking and/or modifying biological CD<sub>1d</sub> function is a lipid derived from a plant, microbe or animal, including a phospholipid, ganglioside, sphingolipid, glycosphingolipid, phosphatidylinositol phosphate, sterol, polyphenol, glyceride or fatty acid. These lipids may influence CD<sub>1d</sub> function by directly  
20        binding the CD<sub>1d</sub> molecule or indirectly by influencing CD<sub>1d</sub> gene expression.

      According to an alternative embodiment the substance capable of blocking and/or modifying biological CD<sub>1d</sub> function is a ceramide, such as ceramide 8 or sphingosine phosphocholine or a ligand of a receptor belonging to the TNF-superfamily, in particular CD95/APO-1/Fas, which induces apoptosis thus interfering with the anti-apoptotic function of  
25        CD<sub>1d</sub>. In another embodiment the objective substance is an organic compound obtained by chemical synthesis.

      It is well established that ceramide glycosylation, via glucosylceramide synthase, and the subsequent build up of glucosylceramides allows cellular escape from stress-induced programmed cell death, conferring cancer cell resistance of a variety of cancers including breast,  
30        skin, colon and epithelial carcinomas, to cytotoxic anti-cancer agents. As CD<sub>1d</sub> can bind

glucosylceramide and is over-expressed by the same multi-drug-resistant cancer cells (e.g. squamous cell carcinoma), it is envisioned that the anti-apoptotic activity of CD<sub>1d</sub> regulates cancer cell resistance to cytotoxic drugs, possibly at the level of protein-glucosylceramide binding. Thus, in principle the substances of the present invention that block and/or modify  
5 endogenous CD<sub>1d</sub> function strongly decrease multi-drug resistance of a variety of cancers including skin, gut and breast cancers.

In principle, the substances of the present invention may also influence the bi-directional trafficking of CD<sub>1d</sub> to and from the membrane.

The substances may be included in any composition suitable for administering the  
10 substance to an individual, in particular a food composition, a cosmetic composition or a pharmaceutical composition.

The pharmaceutical compositions containing at least one of the substances capable of blocking or modifying the CD<sub>1d</sub> surface molecule according to the invention can be administered for prophylactic and/or therapeutic treatments. In therapeutic applications, compositions are  
15 administered to a patient already suffering from a disease, as described herein under, in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as "a therapeutically effective dose". Amounts effective for this will depend on the severity of the disease and the weight and general state of the patient.

In prophylactic applications, compositions containing at least one of the substances capable of blocking or modifying the CD<sub>1d</sub> surface molecule according to the invention are administered to a patient susceptible to or otherwise at risk of a particular disease. Such an amount is defined to be "a prophylactic effective dose". In this use, the precise amounts again  
20 depend on the patient's state of health and weight.

The compounds of the invention are preferably administered with a pharmaceutical acceptable carrier, the nature of the carrier differing with the mode of administration, for example parenteral, intravenous, oral and topical (including ophthalmic) routes.  
25

The desired formulation can be made using a variety of excipients including, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium  
30 saccharin cellulose, magnesium carbonate. This composition may be a tablet, a capsule, a pill, a

solution, a suspension, a syrup, a dried oral supplement, a wet oral supplement, dry tube-feeding, wet tube-feeding etc. In order to control the drug release, sustained-release formulations can also be used.

5 The kind of the carrier/excipient and the amount thereof will depend on the nature of the substance and the mode of drug delivery and/or administration contemplated. E.g., for formulations containing weakly soluble antisense oligonucleotides, micro-emulsions may be employed, for example by using a non-ionic surfactant such as Tween 80 in an amount of about 0.04-0.05% (w/v), to increase solubility. Other components may include antioxidants, such as ascorbic acid, hydrophilic polymers, such as, monosaccharides, disaccharides, and other  
10 carbohydrates including cellulose or its derivatives, dextrans, chelating agents, such as EDTA, and like components well known to those in the pharmaceutical sciences. These various components utilized provide a variety of functions, including regulation of drug concentration, regulation of solubility, chemical stabilization, regulation of viscosity, absorption enhancement, regulation of pH, and the like. For example, in water soluble formulations the pharmaceutical  
15 composition preferably includes a buffer such as a phosphate buffer, or other organic acid salts, preferably at a pH of between about 7 and 8.

It will be appreciated that the skilled person will, based on his own knowledge select the appropriate components and galenic form to target the active compound to the tissue of interest, e.g. the colon, stomach, skin, kidney or liver, taking into account the route of administration  
20 which may be by way of injection, topical application, intranasal administration, administration by implanted or transdermal sustained release systems, and the like.

The objective substance may also be formulated in a cosmetic product, such as lotions, shampoos, creams, sun-screens, after-sun creams, sun-blocker, anti-ageing creams, ointments and/or anti-hair loss liquids. This proves in particular advantageous for essentially blocking CD<sub>1d</sub>  
25 function in the skin and to prevent the adverse effect of sun radiation, photo-ageing and exposure of the skin to free radicals. Thus, e.g. by providing a sun-screen containing in addition to a common agent, absorbing UV-light a substance as defined herein, a protection to the sun may be provided, which by far exceeds anything known so far. This feature is based in particular on the fact that the objective substance will penetrate the skin and exert its effect after having reached  
30 the target molecules. Since this effect will stay for a while, protection to the sun will even be



present in case the sun-screen has been rubbed off or has been washed off, as e.g. during sport etc. Yet, apart from sun-screens the objective substances may be included in common day-creams, lotions etc. to prevent negative effects of the daily environment, including pollution, oxidative stress etc. It will be appreciated that the present cosmetic products will contain a mixture of different ingredients known to the skilled person, ensuring a fast penetration of the objective substance into the skin and preventing degradation thereof during storage.

Another high important composition according to the present invention is food material. In our present society a great deal of food is ingested, such as sausages, salted or grilled meat etc., that contains preservatives, ingredients or substances, that are injurious to the gut. E.g. grilled meat contains aliphatic and aromatic compounds known to be cancerogenic. Also preservatives, that kill micro-organisms contained in food material (e.g. sausages) by manipulating their DNA, will exert a similar effect to cells of the gut. In fact, the number of intestinal cancer is steadily increasing in our society, which may be attributed at least in part to the type of food taken by humans.

Consequently, the present invention provides a food composition that prevents the onset and/or development of such gut disorders, such as a composition selected from the group consisting of milk, or fermented milk products, such as e.g. yogurt, curd, cheese, milk based fermented products, ice-creams, milk based powders, infant formulae, cereal products and fermented cereal based products, mineral water, chocolate or pet food containing at least a substance capable of essentially blocking and/or modifying CD<sub>1d</sub> function. Since the objective compound will be contained in a food material in amounts, that do not affect the original taste thereof, the consumer will not notice any change in the product, but will experience the beneficial effects thereof, namely a protective or even curing effect. Once the food material has been ingested the objective substances will arrive at the target cells, which may be epithelial cells of the gut, i.e. of the stomach or the intestine, and will bind to the CD<sub>1d</sub> receptor and exert its activity. As a consequence, cells, that are already damaged will preferably go to apoptosis instead of being maintained in said damaged form.

Since epithelial cells bearing CD<sub>1d</sub> have been found in a number of organs, such as the liver, the small intestine, the colon, the kidney, the prostate, the uterus, the pancreas, breast, skin and conjunctiva, the choice of the composition as detailed above will, by and large depend on the

target tissue. As will be understood, for skin a cosmetic product might be the composition of choice, while in case of delivering the objective substance directly to the gut or the colon, a food product may be first choice. However, a food product may also be suitable for delivering the objective substance or substances to other organs, such as the kidney or the liver, which will depend on the stability of the substance in the body and its capacity of being absorbed by the body in the gut. Since food is a daily ingested material such a product offers a great variety of different possibilities. Yet, in case the objective substance is prone to degradation in the gut a pharmaceutical composition may be selected, providing e.g. encapsulation or other galenic forms to deliver the objective substance to the target tissue/to target cells.

It will be understood that the concept of the present invention may likewise be applied as an adjuvant therapy assisting in presently used medications. In this respect the pharmaceutical composition of the present invention may be administered together with e.g. cytostatika so as to prevent escape of the tumor treated from the treatment, which sometimes occurs in long term treatments of certain tumors or to assist in killing residual cancer cells not captured with the pharmaceutical regimen. Since the substance(s) of the present invention may easily be administered together with food material special clinical food may be applied containing a high amount of the objective substances. Also melanoma may be directly treated with an antibody medication against melanoma together with a pharmaceutical composition or a cosmetic product as described herein. It will be clear that on reading the present specification together with the appending claims the skilled person will envisage a variety of different alternatives to the specific embodiments mentioned herein.

In principle, the substances according to the present invention may be used for the treatment and/ or prevention of damages in epithelial tissues, such as e.g. in the skin, gut, eye, lung, liver, prostate, breast, kidney and/or in the uterus, which are produced by a stress situation, e.g. by means of a chemical, biological or a physical stress, e.g. by exposure to oxidants or carcinogens, exposure to bacteria, viruses, fungi, lipids derived from surrounding cells and/or microbes, or exposure to UV-irradiation. Likewise, the substances may be utilized for preventing and/or treating hair loss.

Consequently, the substances and/or compositions according to the present invention may be utilized for treating and or preventing damages of the skin, in particular actinic and ageing

damages of the skin such as dryness, actinic keratoses, irregular pigmentation (notably comprising freckling, lentigines, guttate hypomelanosis and persistent hyperpigmentation), wrinckling (notably comprising fine surface lines and deep furrows), stellate pseudoscars, elastosis, inelasticity, telangiectasia, venous lakes, purpura, comedones, sebaceous hyperplasia, acrochordon, cherry angioma, seborrhea keratosis, lentigo, basal cell carcinoma and squamous cell carcinoma, skin burning and/or blistering, cataract formation, epidermal hyperplasia, inflammation, immune suppression, and cancer, e.g. non-melanoma and melanoma skin cancers.

In order to arrive at additional substances having the above characteristics the present invention also provides a method for screening for such substances. In this method epithelial cells are utilized that may be in the form of a primary culture, i.e. directly derived from an individual or in the form of a cell line. For carrying out the method a cell culture is particularly preferred, since it allows for the continuous supply of epithelial cells during the experiments. Care must be taken that the cell culture of epithelial cells used exhibit the same phenotypic traits as do cells of a primary culture or epithelial cells directly obtained from a tissue sample. It will be understood that the person skilled in the art will select the starting material depending on the assay. Hence, if a first round assay is to be carried out a cell culture design seems to be most appropriate, while in case for further rounds, i.e. assessing the activity of potential candidates, the tissue or even the animal model seems to be more appropriate.

The epithelial cells are exposed to a substance of interest for a time period sufficient to ensure a contact of the substance with the cells. In a next step the epithelial cells are exposed to a stress situation, which may be effected e.g. by irradiating the cells with different dosages of UV light, or adding hydrogen peroxide or toxic chemicals to the cell culture. However, the type of stress is not critical as long as the cells are challenged to initiate processes, normally started under stress situations, such as e.g. the production of pro-inflammatory cytokines e.g. IFN- $\gamma$ , TNF- $\alpha$ , IL-1, IL-6, IL-8, apoptosis, altered lipid metabolism, increased production of p53, altered cell signaling as a result of altered patterns of cell surface receptor co-clustering, NF- $\kappa$ B activation, AP1 activation, showing hyperproliferation (anti-apoptosis), altered barrier function etc. It will be understood that also more than one substance may be tested at the same time, that is a cocktail of one or more substances, which might prove beneficial for the second or further round of assaying.

In a next step the effect of said stress on the epithelial cells is determined by assessing one or more of the following features, for example: epithelial proliferation (PCNA: Ouhtit et al., American Journal of Pathology [2000], 156: 201-207; BrUd: Lu Y-P et al., Cancer Research [1999], 59: 4591-4602 ); epithelial apoptosis (Tunel Assay; modification of protocol outlined by  
5 Ouhtit et al., American Journal of Pathology [2000], 156: 201-207); p53 mutation accumulation (Allele-specific polymerase chain reaction [AS-PCR] and single-strand conformation polymorphism [SSCP], Ananthaswamy et al., Nature Medicine [1997], 3: 510-514); production of pro-inflammatory and immuno-modulatory cytokines (e.g. TNF- $\alpha$ , PGE-2, IL-1, IL-6, IL-8, IL-4, IL-10, Platelet Activating Factor, TGF $\beta$ ); markers of inflammation (e.g. COX-2, iNos); and  
10 anti-apoptotic transcription factor (including AP-1, NFkappaB) activity by TaqMan Real-time RT-PCR, ELISA, and Immunohistochemistry; qualitative and quantitative assessment of phospholipids, glycosphingolipid and sphingolipid content (Electron-Spray Tandem Mass Spectrometry); analysis of co-clustering patterns of epithelial cell surface receptor molecules including cytokine receptors (e.g. IL-6), molecules of the TNF-superfamily of receptors (e.g.  
15 CD95/APO-1/Fas) and growth regulating receptors (e.g. EGF, Insulin) by fluorescence resonance electron transfer analysis (FRET); markers of ageing, e.g. elastases, collagenases, metalloproteinases, gelatinase, stromelysins, telomerase.

The results obtained are then compared with a control, which may simply be an assay, wherein the same type of cells are exposed to the same stress conditions with the proviso, that no  
20 compound to be assessed for its CD<sub>1d</sub> blocking capacity is provided. As for the animal model a positive control is represented by a CD<sub>1d</sub><sup>-/-</sup> animal, wherein CD<sub>1d</sub> activity is lacking at all.

The following examples illustrate the invention in more detail without restricting the same thereto.

### **Example 1**

#### **25 Generation of CD<sub>1d</sub> mutant mice**

Mouse CD<sub>1d</sub> is encoded by two genes, CD<sub>1d1</sub> and CD<sub>1d2</sub>, that share a high degree of nucleotide sequence identity (Bradbury et al., EMBO J., 7 (1988), 3081-3086). The product of the CD<sub>1d1</sub> gene is recognized by all anti-CD<sub>1</sub> antibodies that have been described, whereas surface expression of the CD<sub>1d2</sub> product has not yet been demonstrated. In addition, the predicted  
30  $\alpha$ 2 domain of the CD<sub>1d2</sub> gene product lacks an intra-domain disulfide bond that is found in the

$\alpha 2$  domain of all published classic and non-classic MHC class I molecules (Bradbury, supra). This disulphide bond is thought to be critical for the folding of the antigen-binding groove. Thus, the CD<sub>1d2</sub> gene may not encode a functional antigen-presenting molecule, and all functions previously attributed to mouse CD<sub>1</sub> may be effected by the product of the CD<sub>1d1</sub> gene. For this reason, it was decided to introduce a targeted mutation into the CD<sub>1d1</sub> gene, while leaving CD<sub>1d2</sub> intact.

The CD<sub>1d</sub> gene was isolated from a strain 129/Sv phage library with a probe generated by polymerase chain reaction. The targeting construct was prepared using a 2.8 kb Apal fragment containing the 5' region of the CD<sub>1d</sub> gene, a 3.2 kb BamHI-NotI fragment containing the 3' region of the CD<sub>1d</sub> gene (the NotI site in this fragment comes from the pBluescript vector into which phage DNA was initially subcloned), a neomycin resistance gene (neo), and the pBluescript plasmid (Stratagene). This construct was designed to delete a fragment of about 200 bp from the exon encoding the  $\alpha 2$  domain of CD1d1. The strain 129/Sv-derived embryonic stem (ES) cell line TL1 was transfected with the NotI-linearized targeting vector. G418-resistant colonies were selected and isolated as described in Van Kaer *et al.*, Cell 71 (1992), 1205-1214. Genomic DNA from individual clones was digested with EcoRI and hybridized with a 2.3 kb ClaI-EcoRI probe from the 5' end of the CD1d1 gene. Recombination was confirmed by digestion with KpnI and hybridization with a 700 bp BamHI-EcoRI probe from the 3' end of the CD<sub>1d1</sub> gene. Chimeric mice were mated with C57BL/6 mice to score for germline transmission, and heterozygous mutant mice were intercrossed to obtain (C57BL/6x129/Sv) F2 homozygous mutants. Mice were typed for their CD1d1 status by genomic southern blotting with the 5' probe. Mutant mice were healthy and bred normally.

Because the ES cells and mouse strain used to generate mutant animals differ in their TL status (129/Sv is a TL+ strain and C57BL/6 is a TL- strain) all mice used in this study were genotyped for TL. To type mice for their TL status, tail DNA was digested with BglII and hybridized with a TL-specific probe that detects a polymorphism between strains 129/Sv (TL+) and C57BL/6 (TL-) (Pontarotti *et al.*, Proc. Natl. Acad. Sci. USA 83 (1986), 1782-1786). This probe was generated by polymerase chain reaction using a set of primers designed on the basis of published sequences (Pontarotti, supra):

5'-TATACAGAGCTCCGTAGGAC-3' ; and

5'-AGTTGTCTGCAGCCACGAAC-3'.

The CD<sub>1d1</sub> mutant and wild-type mice were housed in a specific-pathogen-free barrier animal facility, accredited by the American Association for Accreditation of Laboratory Animal Care (AAALAC). Animals were used between 12-16 weeks of age at the start of the experiments. They were housed in filter-protected cages with a 12h light-dark controlled cycle, and provided with autoclaved NIH open formula mouse chow and water ad libidum. The institutional Animal Care and Use Committee approved all procedures. Within each experiment all mice were aged- and sex-matched.

It is underlined that other genetic backgrounds can be used for creating a CD<sub>1d</sub> mutant mouse, such as Balb/C genetic background.

### Example 2

#### **UV Irradiation of mice**

A bank of five Philips TL-40W/12 sunlamps (Philips, The Netherlands) was used to irradiate the mice. These lamps emit a spectrum from 270 to 400 nm; 54% of the irradiation was within the UVB range (280-315 nm) of the solar spectrum, with 45% being in the UVA (315-400nm) region and less than 1% in the UV-C (240-280 nm) range. The irradiance of the five bulbs averaged 10 W/m<sup>2</sup>, as measured by a UVB PMA research radiometer.

The dorsal hair of the mice was removed with electric clippers and the mice were placed into a plexiglass box separated into individual compartments by Plexiglas dividers and covered with a wire top which decreased the incident dose by 14%. For each UV-irradiation, the box was placed each time in the same position under the lamps to compensate for the uneven distribution of energy along the length of the bulbs. The mice were exposed once or twice to an incident dose of 86 mJ/cm<sup>2</sup> UVB from five Philips TL-40W/12 sunlamps. Mice were exposed to a second dose of UVB radiation 96h after the first exposure. All mice were analyzed for signs of skin damage 24, 48, 72 and 96 h after their last UVB exposure.

Visually, a clear difference in the degree of skin damage was observed between wild-type and CD1d knockout mice following UVB-irradiation of their shaved dorsums. Whilst clear and significant skin damage (burning, skin lesions) was exhibited by UV-irradiated wild-type mice, no obvious signs of skin damage were detected in UV-irradiated CD1d knockout mice.

### **Example 3**

#### **Measurement of apoptosis in epidermis**

Apoptotic cell death was detected using the DeadEnd™ Fluorometric TUNEL System (Promega) which measures the fragmented DNA of apoptotic cells by catalytically incorporating  
5 fluorescein-12-dUTP at 3' -OH DNA ends using the enzyme Terminal Deoxynucleotidyl  
Transferase (TdT). TdT forms a polymeric tail using the principle of the TUNEL assay. Briefly,  
formaline fixed paraffin embedded tissue sections on slides were deparaffinized twice in fresh  
xylene for 5 min at room temperature. They were washed in 100% ethanol for 5 min and then  
rehydrated sequentially by immersing the sections through graded (100%, 95%, 85%, 70%, 50%)  
10 ethanol washes for 3 min. Afterwards, the sections were immersed in 0.85% NaCl for 5min,  
washed in PBS and then fixed in 4% paraformaldehyde for 15 min followed by two washes in  
PBS. After removing residual fluid from the sections by tapping, each tissue section was covered  
with 20µg/ml proteinase K (Sigma) for 8-10 min at room temperature. After proteinase K  
treatment, tissue sections were rinsed in PBS and then fixed by immersing in 4%  
15 paraformaldehyde for 5 min. This was followed by a wash in PBS, removal of residual fluid by  
tapping and incubation of the sections in equilibrium buffer (Promega) for 5-10 min. After  
equilibration, the sections were incubated in a humidified chamber with TdT enzyme for 1 h at  
37°C. Sections were soaked in stop buffer (SSC; Promega) for 15 min to terminate the reactions  
and then rinsed in three changes of PBS. After rinsing, sections were stained with propidium  
20 iodide solution freshly diluted to 1µg/ml in PBS for 15 min in the dark. They were then washed  
three times in deionized water for 5 min, and afterwards, excess fluid wiped off the area  
surrounding the cells. The sections were then immediately examined under a fluorescence  
microscope.

At 2, 6, 24, 48, 72 and 96h after UV exposure (acute/chronic) a TUNEL Assay  
25 (modification of protocol outlined by Ouhtit et al., American Journal of Pathology [2000], 156:  
201-207), of the skin taken from CD1d<sup>-/-</sup> and wild-type mice was carried out. The results revealed  
that epidermal cells within the skin of CD1d<sup>-/-</sup> mice were undergoing a high degree of apoptosis  
compared to wild-type mice. In contrast, in wild-type skin the epidermal cells were undergoing  
significantly less apoptosis.

#### **Example 4**

##### **Measurement of Epidermal Hyperplasia**

Dorsal skin biopsies were fixed overnight in 4% paraformaldehyde and paraffin embedded. Sections were stained with hematoxylin and eosin (H&E) and viewed by light microscopy.

Following UVB exposure,  $CD_{1d}^{-/-}$  mice exhibited significantly reduced epidermal hyperplasia 48h after the last UVB treatment compared to UV-irradiated wild-type mice.

#### **Example 5**

##### **Gene profiling**

In order to elucidate  $CD_{1d}$  function a gene profiling assay comparing wild-type and  $CD_{1d}$  knockout mouse gene expression had been performed.

Skin tissue was extracted from 5 individual wild-type and  $CD_{1d}$  knockout mice and extracted separately using Trizol kit (Invitrogen AG, Basel, Switzerland) and then Qiagen RNeasy mini-kits (Basel Switzerland) according to manufacturer instructions with DNase I treatment to remove any genomic DNA contamination. RNA samples were quantified by OD then analyzed via dynamic gel electrophoresis with the Agilent Bioanalyser for intact 28S and 18S rRNA (All 28 / 18 ratio's were between 1.6 and 2.0). Study samples were judged to contain sufficient amounts of high-quality RNA for hybridization to GeneChips. As another quality control measure, prior to hybridization with Affymetrix GeneChips (Affymetrix, Inc., Santa Clara, CA), we confirmed that all samples gave strong signals for pre-selected genes, using Affymetrix test chips (Test chip 5' / 3' ratios were less than 3.0).

For skin, 10  $\mu$ g total RNA was the starting material for all individual mouse samples. In general, total RNA was converted to biotinylated cRNA, hybridized in the Affymetrix probe array cartridge, stained, and then quantified. First and second strand cDNA synthesis was performed using the SuperScript Choice System (Invitrogen AG, Basel, Switzerland), according to manufacturer instructions, but using an oligo-dT primer containing a T7 RNA polymerase binding site. Labeled cRNA was prepared with the RNA Transcript Labeling kit (Enzo Biochem Inc., NY). Biotinylated CTP and UTP were used together with unlabeled NTPs in the reaction, and unincorporated nucleotides were removed with Nucleospin columns (Macherey-Nagel, Düren, Germany).



cRNA (20 µg) was fragmented at 94 °C for 35 min in buffer containing 200 mM Tris-acetate pH 8.1, 500mM KOAc, 150 mM MgOAc. Prior to hybridization, fragmented cRNA in hybridization mix ( Buffer containing 100 mM MES, 1M NaCl, 20 mM EDTA, 0.01% Tween 20, 0.5 ng/µl BSA, 0.1 ng/µl herring sperm and Affymetrix controls ), was heated to 95 °C for 5 min, cooled to 45 °C and loaded onto an Affymetrix probe array cartridge. The probe array was incubated for 16 h at 45 °C at constant rotation (60 rpm), then exposed to Affymetrix washing and staining protocol.

This protocol included:

- one wash with non-stringent buffer ( 6X SSPE, 0.01% Tween 20, 0,005% antifoam )
- one wash with stringent buffer ( 100 mM MES, 0.1 M NaCl, 0.01 % tween 20 )
- First stain with 0.01 mg/ml streptavidin-phycoerythrin conjugate (Molecular Probes) in buffer containing 100 mM MES, 1M NaCl, 0.05% Tween 20, 4 mg/ml of BSA.
- one wash with non-stringent buffer ( 6X SSPE, 0.01% Tween 20, 0,005% antifoam )
- Second stain with 3 µg/ml of biotinylated anti-streptavidin + 0.2 mg/ml of IgG in buffer containing 100 mM MES, 1M NaCl, 0.05% Tween 20, 4 mg/ml of BSA.
- Third stain with 0.01 mg/ml streptavidin-phycoerythrin conjugate (Molecular Probes) in buffer containing 100 mM MES, 1M NaCl, 0.05% Tween 20, 4 mg/ml of BSA.
- one wash with non-stringent buffer ( 6X SSPE, 0.01% Tween 20, 0,005% antifoam )

A mathematical method was developed and applied to the raw GeneChip data for the selection of differentially regulated genes. This method moves beyond setting a single fold change cut-off by considering the standard deviation (SD) in the context of absolute expression, or absolute difference intensity (ADI).

The method include the following steps: (A) data processing by the commercially available "MAS5" Affymetrix program (Santa Clara, CA, USA) and rescaling, (B) logarithmic transformation to distribution normality of the rescaled data, (C) multiple hypotheses (one per gene) analysis of variance (ANOVA) testing, (D) the determination of the robust mean within condition SD (equation 1), within bins of 200 genes ordered by mean ADI levels, to determine a significance limit SD between condition, named the REGExpress function (equation 2 from Genome Biology 2001 2(12): preprint0009.1-0009.31); and (E) subsequent ranking of genes by

the p value of the REGExpress and ANOVA, to help focus at effect importance. The selection is made with the p value resulting from multiple hypotheses (one per gene) ANOVA testing and/or with the p value resulting from REGExpress.

5 Probe arrays were scanned at 488 nm using an Argon-ion Laser (made for Affymetrix by Agilent). Readings from the quantitative scanning were analyzed with Affymetrix Gene Expression Analysis Software.

10 The findings are summarized in the tables I to III below. The fold increase (+) or decrease (-) is the statistically significant relative fold increase or decrease of a gene expressed in CD1d knockout mice compared to the same gene expressed in wild-type mice. It becomes clearly evident that blocking CD1d upregulates genes controlling hair follicle development, and down-regulates genes involved in inflammation and cancer development.

Table I  
Genes which regulate hair follicle development

Gene Name	Fold increase/decrease	Mean Wt	Mean CD1d +/-	Biological Function
<b>mmu-crystalline</b>	+27.0	0.922	4.251	thyroid binding protein regulating hair follicle development
<b>PPatched homolog 2</b>	+2.763	3.810	4.826	hair follicle development

15

**Table II**  
**Genes which regulate inflammation**

Gene Name	Fold increase/decrease	Mean Wt	Mean CD1d -/-	Biological Function	Disease Association
TGF beta activated Kinease	+1.743	3.630	4.186	Signalling molecule of the p38-MAPKinase and the Stress activated protein Kinase (SAPK) pathways.	
Rel-A(NfKappaB)	-0.735	7.350	7.043	anti-apoptotic, induction of inflammatory cytokines.	inflammatory disorders
Cytochrome beta	-0.738	6.829	6.525	superoxide generation	
Plasminogen activator inhibitor (PAI-1)	- 0.357	3.906	2.875	Serine protease inhibitor. Regulates fibrolysis.	inflammatory disorders
MRP14	- 0.202	3.943	2.344	Ca <sup>++</sup> dependent regulatory protein in inflammatory responses.	acute and chronic inflammatory responses e.g. Psoriasis
Mast cell protease	- 0.661	6.427	6.014	proteolysis and peptidolysis.	inflammation
P-Selectin	- 0.685	6.439	6.060	Cell adhesion	inflammation
TFII-1	+1.373	5.707	6.024	Transcription factor which regulates c-Fos activity	
Interleukin-6	- 0.268	1.882	0.565	cytokine: multi-functional	inflammation

5

**Table III**  
**Genes which regulate cancer growth/development:**

Gene Name	Fold increase/decrease	Mean Wt	Mean CD1d -/-	Biological Function	Disease Association
v-Rel (NfKappaB)	-0.735	7.350	7.043	oncogenic-transforms cells	cancer
Plasminogen activator inhibitor (PAI-1)	- 0.357	3.906	2.875	serine protease inhibitor	metastatic tumors
P-Selectin	- 0.685	6.439	6.060	adherence	facilitates tumor metastasis.
Cathepsin S	- 0.697	7.545	7.184	Cysteine protease	malignancy
Proliferin	- 0.234	1.870	0.419	regulates angiogenesis	mouse fibrosarcomas
Interleukin-6	- 0.268	1.882	0.565		secreted by basal cell carcinomas and malignant melanomas.
CSF-1 receptor	- 0.750	7.196	6.909	Growth factor regulating cell proliferation.	Cancer

### **Example 6**

Evaluation of the inflammatory response induced by a single topical administration of TPA

Phorbol-12-myristate-13-acetate (TPA) provided by Sigma Aldrich (L'Isle d'Abeau  
5 Chesnes BP701, 38297 Saint Quentin Fallavier, France) is dissolved in acetone at the dose of  
0.01 % (W/V) and 20 µl of the solution is applied topically onto the internal face of the right ear  
of CD<sub>1d</sub><sup>-/-</sup> mice or wild-type mice in order to induce an acute inflammatory response.

The animals are maintained in individual cages with a standard pellet diet in an animal  
room with a 12-hour light-dark cycle. The facilities provide a filtered air with a temperature of  
10 22 +/- 2 °C and a relative humidity of 55 +/- 10 %.

The inflammatory response is quantified 6 hours, 24 hours and 48 hours after application  
by measuring the ear oedema using a micrometer (« oditest » provided by Kroeplin GmbH,  
Postfach 1255 D36372 Schlüchtern, Germany).

The oedema is calculated as follows:

15 (oedema = ear thickness of the treated group – ear thickness of the acetone group).

The mean value of CD<sub>1d</sub><sup>-/-</sup> group is compared to the mean value of the wild-type group  
using the Student's t-test.

### **Example 7**

Evaluation of the inflammatory response induced by a single topical administration of  
20 arachidonic acid

Arachidonic acid (5-8-11-eicosatetraenoic acid) provided by Sigma Aldrich (L'Isle  
d'Abeau Chesnes BP701, 38297 Saint Quentin Fallavier, France) is dissolved in acetone at the  
concentration of 140nM and 25 µl of the solution is applied topically onto the internal face of the  
right ear of CD<sub>1d</sub><sup>-/-</sup> mice or wild-type mice in order to induce an acute inflammatory response.

25 The animals are maintained in individual cages with a standard pellet diet in an animal  
room with a 12-hour light-dark cycle. The facilities provide a filtered air with a temperature of  
22 +/- 2 °C and a relative humidity of 55 +/- 10 %.

The inflammatory response is quantified 1 hour, 2 hours, and 4 hours after application by  
measuring the ear oedema using a micrometer (« oditest » provided by Kroeplin GmbH, Postfach  
30 1255 D36372 Schlüchtern, Germany).

The oedema is calculated as follows:

(oedema = ear thickness of the treated group – ear thickness of the acetone group).

The mean value of  $CD_{1d}^{-/-}$  group is compared to the mean value of the wild-type group using the Student's t-test.

5      **Example 8**

Evaluation of the DTH (delayed-type hypersensitivity) reaction induced by oxazolone

Oxazolone (4-ethoxymethylene-2-phenyl-oxazol-5-one) provided by Sigma Aldrich (L'Isle d'Abeau Chesnes BP701, 38297 Saint Quentin Fallavier, France) is dissolved in acetone at the concentration of 1% (W/V) and 50  $\mu$ l of the solution is applied once daily for 4 days on the abdominal skin of shaved  $CD_{1d}^{-/-}$  mice or shaved wild-type mice.

4 days later the animals are challenged by a single administration (20 $\mu$ l) onto the internal face of the right ear of oxazolone dissolved in acetone at the dose of 0.3%. The post-challenge response is quantified 24 hours and 48 hours after application by measuring the ear oedema using a micrometer (« oditest » provided by Kroeplin GmbH, Postfach 1255 D36372 Schlüchtern, Germany).

The oedema is calculated as follow :

(oedema = ear thickness of the treated group – ear thickness of the acetone group).

The mean value of  $CD_{1d}^{-/-}$  group is compared to the mean value of the wild-type group using the Student's t-test.

20      **Example 9**

Evaluation of skin damages induced by UV irradiation using a solar simulator

A solar simulator (Oriel 81050) equipped with an UVC filter is used to irradiate  $CD_{1d}^{-/-}$  mice or wild-type mice.

Irradiation: UVB + UVA doses and to be precised

25      Effect on epidermis: SBC counts, epidermal hyperplasia measurement

Effect on the dermis: MMP1 and MMP3 expression with immuno-histochemical methods

**Example 10**

Regulation of  $CD_{1d}$  gene transcription by UV radiation and role of  $CD_{1d}$  in regulating UV-induced COX-2 and TNF- $\alpha$  gene transcription

## MICE

Specific pathogen-free male outbred 129/C57BL/6 wild-type and 129/C57BL/6 CD1<sub>d</sub> knockout mice were obtained from L. Van Kaer, Vanderbilt University Medical Center (Nashville, TN, USA). The animals were maintained in facilities in accordance with current Swiss regulations and standards. They were housed in filter-protected cages, and ambient lighting was controlled to provide 12 h light/12 h dark cycles. Autoclaved open-formula mouse chow and water were provided ad libidum. All animal procedures were reviewed and approved by the Institutional Animal care and Use Committee. Within each experiment all the mice were matched for age and sex. The mice were 16 weeks at the start of each experiment.

## UV LIGHT SOURCE

The UVB source was a bank of five Philips TL-40W/12 sunlamps (Philips, The Netherlands). These lamps emit a spectrum from 270 to 400 nm; 54% of the irradiation was within the UVB range (280-315 nm) of the solar spectrum, 45% in the UVA (315-400nm) region and less than 1% in the UV-C (240-280 nm) range. The irradiance of the five bulbs averaged 10 W/m<sup>2</sup>, as measured by a UVB PMA research radiometer. Solar simulated light (UVA + UVB) was produced by a 1000W exon UV solar simulator (Solar Light Company, PA, USA) equipped with a WG-320 atmospheric attenuation filter (1mm thick), a visible/infrared band pass blocking filter (UG-5; 5mm thick), and a dichroic mirror to further reduce visible and infrared energy.

## UV IRRADIATION OF MICE

The dorsal hair of the mice was removed with electric clippers. For mice being exposed to UVB radiation they were placed into a Plexiglass box separated into individual compartments by Plexiglass dividers and covered with a wire top which decreased the incident dose by 14%. For each UVB-irradiation, the box was placed each time in the same position under the lamps to compensate for the uneven distribution of energy along the length of the bulbs. For mice being exposed to solar UV radiation (UVA + UVB) the mice were anaesthetized to immobilize them prior to being exposed to the beam of the solar simulator. The mice were exposed once to an incident dose of 86, 215 or 430mJ/cm<sup>2</sup> UVB from five Philips TL-40W/12 sunlamps. Mice exposed to solar light (UVA + UVB) were exposed once to an incident dose of 1680 (1 min), 16,800 (10 min) or 33,600mJ/cm<sup>2</sup> (20 min) solar radiation.

## UV IRRADIATION OF KERATINOCYTE CELL CULTURES

Confluent cultures of keratinocytes grown in sterile 6-well plates (Corning, Netherlands) were submitted to a single dose ( $5700\text{mJ}/\text{cm}^2$ ) of solar UV irradiation. Treatment was performed without plastic lids after having removed medium and replaced it by sterile HBSS. Control cultures were not irradiated. After UV exposure, HBSS was removed and medium put back on cultures. The cells were incubated at  $37^\circ\text{C}$  with 5%  $\text{CO}_2$  and at various time points thereafter harvested for RNA.

## IMMUNOSTAINING OF MOUSE TISSUE

Biopsies of wild-type mouse skin were fixed in formaline before being embedded in paraffin. Cross sections ( $5\mu\text{m}$  thick) of paraffin embedded tissues were made, deparaffinized by gentle heating, de-hydrated and rehydrated using the following procedure: 2 times for 3 min in Xylol, 3 min in Ethanol 100%, 3 min in Ethanol 95%, 3 min in Ethanol 80% and 3 min in PBS 1X. Fresh skin was also embedded in Tissue-Tek (4583, Sakura Finetek, Torrance, USA) and frozen in liquid nitrogen. The sections were then rehydrated in PBS 1X for few minutes. Sections were stained using the anti-mouse CD1d 1H1 primary mAb and developed using the mouse Histostain-plus kit (ZYMED Laboratories Inc., San Francisco, USA).

## EXTRACTION OF TOTAL RNA FROM SKIN OR CELL LYSATES

Treated and control cultures of human keratinocytes grown in 6-well plates were placed on ice and washed twice using PBS 1X at  $4^\circ\text{C}$ . Cell lysate was obtained by scraping the cells in 350 $\mu\text{l}$  of lysis buffer RLT (74104, Qiagen AG, Basel, Switzerland) supplemented with 1% of  $\beta$ -mercaptoethanol and by briefly vortexing them. QIAshredder columns (79656, Qiagen AG, Basel, Switzerland) were used to homogenize cell extracts by centrifugation at  $13,000\times g$  for 2 min. Total RNA was then prepared using RNeasy kits (74104, Qiagen AG, Basel, Switzerland) according to the manufacturer's protocols. Genomic DNA contamination was removed with on-column DNase digestion using a RNase-free DNase Set (79254, Qiagen AG, Basel, Switzerland). Skin samples of  $1\text{cm}\times 1\text{cm}$  were cut into small pieces and homogenized in 1ml of TRIZOL Reagent (15596-026, Invitrogen AG, Basel, Switzerland) using a rotor-stator homogenizer (Polytron, Kinematica, Luzern, Switzerland). The supernatant obtained after centrifugation at  $12,000\times g$  was recovered in a fresh tube and incubated for 5min at room temperature. 0.2ml of chloroform was added to the tube, which was vigorously shaken for 15sec

and incubated at room temperature for 2-3min. Samples were centrifuged at 12,000xg for 15min at 4°C. The upper aqueous phase was transferred to a fresh tube and total RNA precipitated using 0.5ml of isopropyl alcohol for 10min at room temperature. The RNA pellet obtained by centrifugation at 12,000xg for 10min at 4°C was washed with 1ml of 75% EtOH followed by centrifugation at 7,500xg for 5min at 4°C. The RNA pellet was finally dried at room temperature and dissolved in 40µl of RNase free water by incubating the samples 10min at 55-60°C. Possible DNA contamination was removed with on-column DNase digestion using a RNase-free DNase Set.

#### SEMI-QUANTITATIVE RT-PCR

##### A. Reverse transcription-polymerase chain reaction and PCR reaction

5µg of total RNA were reverse transcribed by oligo-dT priming to first strand cDNA using the Superscript First-Strand Synthesis System for RT-PCR (11904-018, Invitrogen AG, Basel, Switzerland) according to the manufacturer's instructions. PCR of cDNA was performed to either detect specific expression of a single gene (single PCR) or multiple genes (Multiple gene PCR). For single PCR, 48µl of PCR master mix containing 5µl PCR Buffer, 3µl 25mM MgCl<sub>2</sub>, 1µl 10mM dNTPs, 0.5µl 50µM of both sense and anti-sense oligonucleotides, 3µl DMSO, 34.5µl of water and 0.5µl of 5U/µl Taq DNA Polymerase was added to 2µl of cDNA. All the reagents were purchased from Invitrogen (15558-026 and 18427-013, Basel, Switzerland). The number of cycles and the annealing temperature applied to amplify cDNA samples were specific to each gene tested, one cycle consisting of 30s at 94°C, 30s at x°C and 30s at 72°C, each amplification being preceded by 2min at 94°C and finished by 3min at 72°C. Kit MP-70211 (Maxim Biotechnologies, San Francisco, USA) for multiple gene PCR of genes implicated in apoptosis and inflammation were used as instructed. Prior to using each kit, the condition for running multiple reverse and forward primers at the same time to detect multiple genes was determined. The conditions for using kit MP-70211 which contained primers for detecting TNF-α and COX-2 genes, were as follows: 96°C for 1min and 60°C for 4 min (cycles 2x); 94°C for 1min and 60°C for 2 min (cycles 29x); 70°C for 10 min (cycle 1x) and 25°C soak. The DNA sequence of the reverse and forward primers used the MPCR kit for detecting multiple genes under one set of conditions were proprietary and thus are not described in this report.



## Primer Sequences and Number of Cycles of Amplification

### Human:

Gene	Primer	Sequence (5'- 3')	Annealing temper.	No. of cycles	Product Size
GAPDH	sense	AAT CCC ATC ACC ATC TTC CA	52	16	558
	antisense	GTC ATC ATA TTT GGC AGG TT			
CD1d	sense	GCT CAA CCA GGA CAA GTG GAC GAG	66	27	452
	antisense	AGG AAC AGC AAG CAC GCC AGG ACT			

### 5 Mouse:

Gene	Primer	Sequence (5'- 3')	Annealing temper.	No. of cycles	Product Size
GAPDH	sense	TTC ACC ACC ATG GAG AAG GC	60	22	236
	antisense	GGC ATG GAC TGT GGT CAT GA			
CD1d.1	sense	ACG TCC TGG CAG ACA GTC CCA GG	60	24	706
	antisense	TTA ATG TTG AAA AGA GCG TAC TGG C			

### B. Relative Quantification of mRNA levels

Amplification of the genes was analyzed by loading 10µl of the PCR products on a 3% agarose gel which was run in a 1XTAE buffer containing 2% Ethidium Bromide at 150V for 30min. The PCR products were visualized as fluorescent bands under UV light. Gels were scanned using a Kodac DC 120 Camera and fluorescence intensity of the bands was quantified using the Software Scion Image β 4.02 Win (Scion Corporation, Maryland, USA).

While studies of CD1d proteins in the murine system suggest a widespread and constitutive expression on many hematopoietic cell types as well as intestinal epithelial cells, and hepatocytes, it was not known whether this molecule is expressed by normal and/or UV exposed mouse skin cells, especially keratinocytes. To address this question, mouse skin from unirradiated and UVB-irradiated wild-type mice was fixed in formaline, sectioned and stained using an anti-mouse CD1d mAb (1H1) to detect CD<sub>1d</sub> protein. Detection of CD<sub>1d</sub> protein in normal unirradiated skin was negative (data not shown). However, CD1d protein was detected (brown color) in the epidermis and dermis of UVB-irradiated mouse skin (Fig. 5). Staining was largely confined to the more differentiated layers of the skin (stratum granulosum and stratum corneum) and at the cellular level was localized to the cytoplasm and nuclear membrane.

Thus, UVB-induced mouse skin damage/burning may be directly regulated at the level of the mouse keratinocyte rather than by antigen-presenting cells (locally or systemically).

#### CD1D GENE TRANSCRIPTION IS REGULATED BY UV RADIATION

Having demonstrated that UVB-induced skin damage is regulated by CD<sub>1d</sub> and that CD<sub>1d</sub> protein is expressed by mouse epidermal cells (keratinocytes), it was next important to establish whether skin CD1d expression is regulated by UV radiation. Any indication that skin CD1d expression is regulated by UV radiation would suggest that modulation of CD1d levels in skin is a critical factor responsible for regulating UV-induced skin damage. To address this question, the shaved dorsum of wild-type mice was exposed to a single dose (86mJ/cm<sup>2</sup>) of UVB radiation and at various times post irradiation (6, 24, 48, 72 and 96h) the irradiated skin was excised, RNA extracted and purified, and CD<sub>1d</sub> mRNA levels determined by semi-quantitative RT-PCR. As a control, normal non-irradiated mouse skin was excised, RNA extracted and purified and CD1d mRNA levels determined by semi-quantitative RT-PCR.

As shown in Fig. 6, the level of CD<sub>1d</sub> mRNA in whole mouse skin which decreased as early as 6h after UVB exposure was significantly reduced 24h post irradiation compared to levels detected in normal non-irradiated skin. In contrast, 48, 72 and 96 hours following UVB exposure CD1d mRNA levels were raised above the levels detected in normal unirradiated control skin. To further validate our studies on the effect of UVB radiation on skin CD1d gene transcription, we exposed the shaved dorsum of wild-type mice to varying doses of solar UV irradiation (UVB +UVA) - 1680 mJ/cm<sup>2</sup> (1 min), 16,800 mJ/cm<sup>2</sup> (10 min) or 33,600 mJ/cm<sup>2</sup> (20 min) of solar UV. At 6 and 72h post irradiation the irradiated skin was excised, RNA extracted and purified, and CD<sub>1d</sub> mRNA levels determined by semi-quantitative RT-PCR (Fig. 7). As with UVB exposure, we observed a similar decrease and increase in CD1d mRNA levels 6 and 72h following solar UV irradiation, respectively, regardless of the UV dose, suggesting that the response of skin CD<sub>1d</sub> gene transcription to UV radiation is an important event in the skin's response to the damaging effects of UV exposure.

#### HUMAN KERATINOCYTE CD1D GENE TRANSCRIPTION IS REGULATED BY SOLAR UV RADIATION

In an attempt to address whether human CD<sub>1d</sub> gene transcription is regulated by UV radiation we investigated whether cultured human keratinocytes exhibit a similar gene

transcription kinetic profile in response to UV irradiation. At different time points following exposure of triplicate DK7 cell keratinocyte cultures to a single dose of 5700mJ/cm<sup>2</sup> solar UV radiation, the cells were harvested for RNA and semi-quantitative RT-PCR performed to determine the relative level of CD1d mRNA (Fig. 8). As observed with UV irradiated (UVB or solar) mouse skin, CD1d mRNA levels decreased 6h post- irradiation compared to normal non-irradiated controls. Analysis of CD1d mRNA levels 10h post-irradiation revealed that these levels had further decreased compared to the levels detected in normal non-irradiated cell cultures. Between 16 and 48h hours after UV exposure, the level of CD1d mRNA increased proportionally; a pattern also observed in the skin of UV-irradiated whole wild-type skin suggesting that UV-induced CD1d gene transcription in mouse skin was likely being regulated at the level of the keratinocyte.

Human keratinocyte CD1d gene transcription is responsive to UV radiation and appears to be regulated in a similar manner to mouse skin CD1d implying that a) skin CD1d plays a critical role in regulating the response of skin to UV irradiation and b) modulation of CD1d levels in skin is a critical factor responsible for regulating UV-induced skin inflammation/damage.

#### GENE TRANSCRIPTION OF KEY GENES WHICH REGULATE SKIN INFLAMMATION IS DIMINISHED IN UVB IRRADIATED CD1d KNOCKOUT MOUSE SKIN

To further validate CD1d as a critical molecule responsible for regulating UVB-induced skin inflammation/damage we next investigated whether COX-2 and TNF- $\alpha$  gene transcription (key genes responsible for regulating UVB-induced skin inflammation/damage) is deregulated in UV-irradiated CD1d knockout mouse skin. It was found that COX-2 and TNF- $\alpha$  mRNA levels in CD1d knockout mouse skin were inhibited 48 and 72h after UV irradiation (Fig. 9). Since UV-induced skin damage/inflammation in wild-type mice is observed at 48 and 72h after UV exposure these data demonstrate that skin CD1d mediates UV-induced skin inflammation/damage by inducing COX-2 and TNF- $\alpha$  gene transcription.

#### Example 11

Inflammatory cytokines synthesis in UV-irradiated skin of CD1d Knockout mice is decreased compared to wild-type control mice.

### UV irradiation of mice

The mice were exposed once to an incident dose of 200 mJ/cm<sup>2</sup> UVB radiation. Three month old female inbred 129/C57BL/6 WT and 129/C57BL/6 CD1d KO mice were involved in this study (n=4).

### 5 Cytokine quantification

8 mm punch biopsies of skin were harvested at 0h, 24h, 48h, 72h, 96h and 168h post-irradiation and immediately frozen in liquid nitrogen. IL-6 and MIP1- alpha were quantified in skin homogenates using classical ELISA methods.

10 In WT mice UV-B irradiation induces a high up-regulation of inflammatory cytokines synthesis, 48 hours post-irradiation, whereas in CD1d KO mice synthesis of IL-6 and MIP1-alpha protein is significantly reduced. This demonstrates a major role for CD1d in UVB-induced cutaneous inflammation.

### Example 12

Hydrocortisone down-regulates chemical stress-induced CD1d gene transcription.

15 Primary human keratinocytes were grown in complete KGM before being exposed to 300µM H<sub>2</sub>O<sub>2</sub> as a stress factor. 48 hours after seeding, KGM medium was replaced by KGM without hydrocortisone and cultures were treated with 300 µM of H<sub>2</sub>O<sub>2</sub>. Total RNA was extracted at different time after treatment and CD1d mRNA quantified by Real Time PCR.

20 For Taq Man Assays, Applied Biosystems recommends to use 10 to 100ng of initial RNA quantity per well. Consequently, first strand cDNA synthesis was performed in a 20µl volume using 1µg of total RNA and 150µg of random hexamers following the manufacturer's recommendations (Superscript<sup>TM</sup> First-Strand Synthesis System for RT-PCR, 11904-018, Invitrogen). 1µl of the resulting cDNA samples was used for amplification by Real Time PCR.

25 The sets of primers and probes used for detection of CD1d cDNA were provided by Applied Biosystems as Assays on Demand (respectively Hs00174321\_m1 and Hs00166289\_m1). The primers and probes for the housekeeping gene GAPDH were provided as PDARS (4310884E, Applied Biosystems).

30 All the cDNA samples were tested in triplicate. PCR reaction mixtures were prepared on ice in micro centrifuge tubes. For one replicate, a pre-mix of 24µl was made using 1.25µl of 20X Target or Control mix, 10.25µl of water and 12.5µl of 2X TaqMan Universal Master Mix, and

added to 1µl of cDNA. The PCR reaction mixtures were gently and quickly centrifuged before being aliquoted at the rate of 25µl per well of a 96-wells plate. The plate was sealed, centrifuged at 2000rpm for 30 seconds and placed in a 5700 Sequence Detection System for thermal cycling and fluorescence analysis using the following PCR program:

- 2min at 50°C
- 10min at 95°C
- 40 cycles of 15 sec at 95°C and 1 min at 60°C

Results were analyzed using the GeneAmp® 5700 SDS software. Amplification plots showing amplification of cDNA of interest in function of the number of cycles were obtained.

The gene expression fold changes obtained in the test condition compared to the control condition were determined by the comparative Ct method using the following formula:

$$\text{Fold changes} = 2^{-\Delta\Delta\text{Ct}} = 2^{-(\Delta\text{Ct test} - \Delta\text{Ct control})}$$

$$\text{where } \Delta\text{Ct} = \text{Ct}_{\text{target gene}} - \text{Ct}_{\text{housekeeping gene}}$$

As shown in Fig. 11, modulation of CD<sub>1d</sub> gene expression is observed over time when cells are exposed to H<sub>2</sub>O<sub>2</sub>. In presence of Hydrocortisone, the pattern of CD<sub>1d</sub> gene expression obtained following H<sub>2</sub>O<sub>2</sub> challenge differed in that hydrocortisone suppressed CD<sub>1d</sub> transcription.

Thus, Hydrocortisone is able to down-regulate CD<sub>1d</sub> expression in cells subjected to a stress.

### **Example 13**

Phospholipid levels are disregulated in the skin and the intestine of CD<sub>1d</sub> knockout mice compared to wild-type skin.

Mice: Female inbred C57BL/6 CD1d<sup>-/-</sup> and wild-type C57BL/6 mice aged 5 months were sacrificed and the respective tissue excised. The pieces of skin/intestinal tissue from each mouse were snap frozen using liquid nitrogen. They were then analysed for lipid content.

The main family of lipids regulated by CD1d in skin were phospholipids.

		nMolar per gram of skin tissue	
		CD1d -/-*	Wild-type
5	Spingomyelin	33 +/- 30.4	176 +/- 116
	Lysophosphatidylcholine	3.8 +/- 3.7	10.0 +/- 4.1
10	Phoshatidylcholine	35.1 +/-21.1	8.5 +/- 12.9
	Phosphatidylserine	67 +/- 30.4	115 +/- 33
15			

\*The values are statistically significantly different from wild-type control ( $p < 0.05$ )

### Sphingomyelin


It is a ubiquitous component of animal cell membranes, where it is by far the most abundant sphingolipid. Indeed, it can comprise as much as 50% of the lipids in certain tissues, though it is usually less abundant than phosphatidylcholine. For example, it makes up about 10% of the lipids of brain. It is the single most abundant lipid in erythrocytes of most ruminant animals, where it replaces phosphatidylcholine entirely. In this instance, there is known to be a highly active phospholipase A that breaks down the glycerophospholipids, but not sphingomyelin. Like phosphatidylcholine, sphingomyelin tends to be most abundant in the plasma membrane, and especially in the outer leaflet, of cells.

Now, it is known that sphingomyelin (and other sphingolipids) and cholesterol may be located together in specific sub-domains ('rafts' or related structures termed 'caveolae') of membranes. As sphingolipids containing long, largely saturated acyl chains, they pack more tightly together, thus giving sphingolipids much higher melting temperatures than membrane glycerophospholipids. This tight acyl chain packing is essential for raft lipid organization, since the differential packing facility of sphingolipids and phospholipids is believed to lead to phase separation in the membrane, giving rise to sphingolipid-rich rafts ('liquid-ordered' phase) surrounded by glycerophospholipid-rich domains ('liquid-disordered' phase). Interactions

between specific cellular proteins and lipids in these rafts are believed to be important in signalling mechanisms implicating an important role for sphingomyelin in regulating cell signaling.

**Sphingomyelin is a key lipid in signal transduction processes involved in apoptosis.**

Also, sphingomyelin serves as a precursor for ceramides, long-chain bases and sphingosine-1-phosphate, as part of the 'sphingomyelin cycle', and many other important sphingolipids. (see figure below). Some of these have functions as intracellular messengers, and others are essential membrane constituents



### Lysophosphatidylcholine

- a phospholipid that is pro-inflammatory
- elevated in lesional psoriasis
- intracutaneous injection induces skin inflammation
- formed by the action of **phospholipaseA2** which is the rate limiting step in the production of arachadonic acid. ([link to regulation of COX-2 by CD<sub>1d</sub>](#)).

For the large intestine the following results were obtained:

			Large Intestine	
			nMoles per gram of Tissue	
Lipid Class	Saturation	Fatty Acid Family	CD1d-/-*	Wild-type
Cardiolipin	Saturated	Stearic Acid	405 ± 89	950 ± 442
		Total	405	950
	Unsaturated	Vaccenic Acid	74 ± 21	167 ± 45
		Oleic Acid	216 ± 42	377 ± 86
		α Linolenic Acid	23 ± 9	43 ± 9
		DHA	164 ± 92	596 ± 278
		Linoleic Acid	781 ± 210	2066 ± 727
		DGLA	36 ± 12	60 ± 16
		Total	1294	3309
Total Cardiolipin			1699	4259
Lysophosphatidylcholine	Saturated	Myristic Acid	78 ± 41	27 ± 5
		Arachidic Acid	7 ± 3	3 ± 0.5
		Total	85	30
	Unsaturated	Eicosenoic Acid	9 ± 5	3 ± 2
		Erucic Acid	234 ± 143	17 ± 36
		Eicosadienoic Acid	153 ± 98	30 ± 61
		DGLA	11 ± 5	4 ± 1
		Docosadienoic Acid	12 ± 8	2 ± 3
		Total	419	56
Total Lysophosphatidylcholine			504	86
Free Fatty Acids	Saturated	Pentadecanoic acid	31 ± 10	17 ± 5
		Total	31	17
	Unsaturated	Nervonic acid	9 ± 5	2 ± 4
		Total	9	2
Total Free Fatty Acids			40	19
Cholesterol Ester	Unsaturated	Eicosapentaenoic acid	5 ± 3	1 ± 3
		Palmitelaidic acid	49 ± 27	13 ± 8
		Total	54	14
Diglyceride	Unsaturated	Eicosenoic acid	11 ± 8	33 ± 16
		Total	11	33
Phosphatidylcholine	Unsaturated	Linoleic acid	2551 ± 2321	6398 ± 2862
		Total	2551	6398
Phosphatidylserine	Unsaturated	Linoleic acid	501 ± 105	1102 ± 338
		Total	501	1102

\* All values were statistically significantly different from wild-type groups (p < 0.05)



For the small intestine the following results were obtained:

			Small Intestine	
			nMoles per gram of Tissue	
Lipid Class	Saturation	Fatty Acid Family	CD1d-/-*	Wild-type
Cardiolipin	Unsaturated	Eicosenoic acid	12 ± 7	21 ± 3
		DHA	178 ± 124	480 ± 121
		Total	190	501
Phosphatidylcholine	Saturated	Behenic acid	13 ± 10	27 ± 10
		Total	13	27
	Unsaturated	Mead acid	7 ± 4	15 ± 4
		Eicosatetraenoic acid	2 ± 3	7 ± 3
		DGLA	154 ± 96	310 ± 115
		Docosadienoic acid	5 ± 4	10 ± 3
		Total	168	342
Total Phosphatidylcholine		181	369	

\* All values were statistically significantly different from wild-type groups (p< 0.05)

This above data support a role for CD<sub>1d</sub> in the regulation of phospholipid metabolism which controls inflammatory processes.

It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

## ABSTRACT

The present invention pertains to a method for preventing and/or treating epithelial tissue damage, such as is effected by inflammatory reactions, ageing or cancer and/or to prevent and/or treat hair loss. In particular, the present invention relates to substances and/or compositions  
5 modifying, in particular blocking endogenous CD<sub>1d</sub> function. According to another aspect the present invention also provides a method for screening for compounds suitable for use in the method and the composition of the present invention.

**Marked-Up Version of Substitute Specification**

**SPECIFICATION**

**TITLE OF THE INVENTION**

**“PREVENTING OR TREATING EPITHELIAL TISSUE DAMAGE OR HAIR LOSS”**

5

**BACKGROUND OF THE INVENTION**

The present invention pertains to a method for preventing and/or treating epithelial tissue damage, such as is effected by inflammatory reactions, ageing or cancer and/or to prevent and/or treat hair loss. In particular, the present invention relates to substances and/or compositions modifying, in particular blocking endogenous CD<sub>1d</sub> function. According to another aspect the present invention also provides a method for screening for compounds suitable for use in the method and the composition of the present invention.

**SUMMARY OF THE INVENTION**

15 The most prominent epithelial tissue in living beings is the skin, which represents the largest organ in the organism. The system of skin integument, which comprises the epidermis, dermis and the stratum corneum, correlates with those of internal organs and concurrently interacts with the surroundings. Being the interface between the environment and organism itself, the skin is heavily influenced by external factors and also variable parameters of the organism's inner system. The skin's regulative mechanisms need, therefore, always be active to induce systemic changes necessary to maintain normal pathological events concerning skin integument morphology and activities. A great deal of processes assuring the adequate consumption of increased affluence of energetic and plastic substances according to the skin's needs become guarantors of morphological and functional stability of skin structures. So, the state of integuments determines the realization of metabolic processes necessary for skin cell viability and activity leading to the presence of healthy skin peculiarities such as barrier function, elasticity, turgor properties, humidity, pigmentation etc..

25 30 During the lifetime of a living being different signs, characteristic of ageing, appear on the skin, with the principal clinical signs being the appearance of fine lines and deep wrinkles which increase or are accentuated with age. Moreover, the skin's complexion is generally

modified and diffuse irritations and occasionally telangiectasias may come into existence on certain areas.

These signs of ageing are even promoted by exposure of the skin to exogenous influences, such as e.g. UV-radiation, pollutants, free radicals or chemical substances.

5        Moderate UV exposure generally causes the well known effects of reddening the skin with an accompanying inflammation reaction, known as erythema. This phenomenon, often referred to as "sunburn", is painful and commonly results in a subsequent peeling of the skin.

10        Moreover, excessive UV-exposure of the skin may also lead to the onset of severe disorders, such as carcinogenesis, the most common tumours being the basal cell carcinoma (BCC), followed by squamous cell carcinoma (SCC), and more rarely malignant melanoma. Apart from damages on the DNA-level also immuno-suppression caused by UV exposure seems to account for both, non-melanoma and melanoma cancer promotion. It is presently acknowledged that photo-induced immuno-suppression permits the initiated tumour cell to evade recognition and rejection by normal immunological mechanisms, to remain latent for extended  
15        periods, and to eventually proliferate into a tumour. This concept concurs with the findings that immuno-compromised patients, whether genetically (xeroderma pigmentosum) or pharmacologically, such as e.g. organ transplant recipients, have a higher incidence of skin cancer as compared to people with a properly functioning immune system.

20        In the art several means have been proposed to prevent destructive effects of environmental factors on epithelial cells, in particular skin epithelial cells.

25        As regards protection to sun radiation "sun blocks" or "sunscreens" have been made available, which are applied to the skin prior to sun exposure. Typically, sunscreen compositions contain chemical agents, such as certain benzophenones, dibenzylmethanes or substituted para-aminobenzoates, i.e. compounds absorbing ultraviolet radiation, so that it cannot penetrate the skin. However, some of the compounds used for this purpose have shown to lack sufficient light stability and may even become toxic over long term application. In addition, they must stay continuously on the surface of the skin at the time of exposure to be effective. However, sunscreens are easily rubbed off or washed off by sweating or swimming and can also be lost by penetration into the skin.

Another means to prevent skin deterioration or ageing, respectively, is to provide compounds scavenging free radicals. In this respect EP 0 761 214 discloses singlet oxygen quenchers comprising aniline derivatives and difurfuryl amine derivatives, which are reported to reduce the oxidative stress to the skin.

5 Yet, all these means and methods are not sufficiently capable to protect the skin from the growing challenge in our environment. To this contributes an increased atmospheric pollution and also social behaviour, according to which sun-tan is associated with health, beauty and status. As a consequence many people expose their skin to sun radiation to acquire a tan in spite of the negative results accompanying such behaviour being well known. This problem even gets  
10 more prominent with the ozone shield covering the earth becoming thinner, resulting in a heavier exposure of living beings to UV radiation.

Consequently there is a need in the art to provide a better protection of the skin to environmental factors, such as stress or sun radiation.

Accordingly, an object of the present invention is to obviate the drawbacks of the prior  
15 art and to provide such means in order to protect the skin from unfavourable influences encountered in the environment, in particular from oxidative or chemical stress or sun radiation.

This problem has been solved by providing a substance, that is capable to essentially modify, in particular block the endogenous CD<sub>1d</sub> function in epithelial cells.

Additional features and advantages of the present invention are described in, and will be  
20 apparent from, the following Detailed Description of the Invention and the figures.

#### BRIEF DESCRIPTION OF THE FIGURES

~~In the figures,~~

Fig. 1A. Wild-type mice exhibit skin damage (burning) following exposure to a single  
25 dose (86mJ/m<sup>2</sup>) of UVB radiation.

Fig. 1B. Wild-type mice exhibit skin damage (burning) following exposure to a single dose (86mJ/m<sup>2</sup>) of UVB radiation. (Close-up).

Fig. 1C. CD1d knockout mice show no obvious signs of skin damage following exposure to a single dose (86mJ/m<sup>2</sup>) of UVB radiation.

Fig. 1D. CD1d knockout mice show no obvious signs of skin damage following exposure to a single dose ( $86\text{mJ/m}^2$ ) of UVB radiation. (Close-up).

Fig. 2 Difference in degree of UVB-induced skin damage between wild-type (Right) and CD1d knockout (Left) mice exposed to two doses ( $86\text{mJ/m}^2$ ) of UVB radiation.

5 Fig. 2A. Damaged (lesions) dorsal skin of wild-type mice exposed to two doses ( $86\text{mJ/m}^2$ ) of UVB radiation (Close-up).

Fig. 2B. Undamaged dorsal skin of CD<sub>1d</sub> knockout mice exposed to two doses ( $86\text{mJ/m}^2$ ) of UVB radiation.

10 Fig. 3. CD<sub>1d</sub> knockout mice exhibit increased epidermal apoptosis in their dorsal epidermis compared to wild-type mice, as measured by TUNEL. Wild-type (A) and CD1d knockout (B) mouse skin not exposed to UV-irradiation. Wild-type (C) and CD<sub>1d</sub> knockout (D) mouse skin 48h after a single exposure ( $86\text{mJ/m}^2$ ) to UV-B radiation.

Fig. 4 a and b are graphs indicating the approximate amount of CD<sub>1d</sub> in different tissues in mice and human.

15 Fig. 5 shows that CD<sub>1d</sub> protein is expressed in the epidermis of mouse skin 72h following exposure to a single dose ( $430\text{mJ/cm}^2$ ) of UVB radiation;

Fig. 6 shows that murine skin CD<sub>1d</sub> gene transcription is regulated following UVB irradiation;

20 Fig. 7 shows that murine skin CD<sub>1d</sub> gene transcription is regulated following solar simulated light irradiation;

Fig. 8 shows that CD<sub>1d</sub> gene transcription in immortalized (DK7) human keratinocytes is regulated following solar UV irradiation;

Fig. 9. shows that COX-2 and TNF-alpha mRNA levels are down-regulated in UVB-irradiated CD<sub>1d</sub> knockout mouse skin.

25 Figure 10 a and b) show that mouse skin IL-6 and MIP1-alpha protein levels 48h after UVB irradiation are significantly decreased in CD<sub>1d</sub> KO mice.

Fig. 11 shows that hydrocortisone suppresses CD<sub>1d</sub> transcription in cells exposed to a chemical stress; and

Fig. 12 shows that CD<sub>1d</sub> is expressed in human hair follicles.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention is essentially based on the finding that CD<sub>1d</sub>, a transmembrane protein expressed by a number of different cells, in particular epithelial cells, modulates a variety of different responses of the cell to stress. As will become evident from the following detailed description of the preferred embodiments, essentially modifying, specifically blocking the endogenous CD<sub>1d</sub> function in cells bearing said membrane molecule allows to prevent the detrimental effects of stress, including ultraviolet radiation-induced skin damage, e.g. as a result of burning, epidermal hyperplasia, mutant p53 accumulation, inflammation, immune suppression and skin ageing. Even more surprising is the finding that when essentially blocking CD<sub>1d</sub> function in epithelial cells induction of cancer in said cells, i.e. basal cell carcinoma, squamous cell carcinoma, malignant melanoma, colon, breast, liver, prostate, kidney, pancreas cancer etc., may be prevented. In addition, it has been surprisingly found that modifying, in particular blocking CD<sub>1d</sub> function influences hair growth and/or development.

CD<sub>1d</sub> as such is a type 1 transmembrane MHC class 1 like protein that non-covalently associates with  $\beta_2$ -microglobulin. The CD<sub>1d</sub> molecule is recognized by a T-cell receptor of natural killer T-cells (NKT) which play a role in immune modulatory and effector reactions. It has been demonstrated that CD<sub>1d</sub> may present lipids to NKT cells for their activation, which notion is supported by the CD<sub>1d</sub> crystal structure having two highly hydrophobic grooves, necessary for presenting hydrophobic molecules such as lipids to the immune system.

In the studies leading to the present invention it has surprisingly been noted that CD<sub>1d</sub> gene transcription in mouse skin is responsive to external stress, such as UV radiation, which finding has been confirmed in human keratinocytes. In addition it has been noted that skin CD<sub>1d</sub> mediates UV-induced skin damage/inflammation by inducing COX-2 and TNF- $\alpha$  gene transcription and also inhibiting UV-induced apoptosis.

Without wishing to be bound to any theory it is currently assumed that one of the endogenous tasks of CD<sub>1d</sub> in living organisms is to directly control normal epithelial cell homeostasis. Normal skin homeostasis is dependent on the critical and fine tuned balance between epidermal differentiation, apoptosis, proliferation and anti-apoptosis of epidermal cells. In the skin, these processes are regulated via lipids, in particular by means of ceramides and

glucosylceramides (sphingolipids). While the nucleated cell layers generate glucosylceramides (GlcCer), the proportions of GlcCer to Cer decrease late in epidermal differentiation, with the Cer content peaking in the stratum corneum acting as extracellular constituents of the epidermal permeability barrier. In addition to their structural properties, ceramides are associated with inhibition of cellular proliferation, induction of cellular differentiation and programmed cell death. In contrast, GlcCer induce cell proliferation and inhibit programmed cell death.

Based on the findings in the present invention, CD<sub>1d</sub> appears to be one of the receptors via which the above mentioned lipids might fulfill their biological task. Specifically, CD<sub>1d</sub> seems to negatively regulate apoptosis. In consequence, in cells under a stress situation, e.g. when exposed to UV-radiation, CD<sub>1d</sub> supports a continued existence of said stressed cells, even when their genetic material is damaged and/or mutated, which damaged cells will contribute to inflammation processes induced and eventually account for the phenomenon of ageing or eventually tumour development.

In blocking and/or modifying endogenous CD<sub>1d</sub> function, apoptosis of cells under stress may be promoted, instead of their survival and propagation, with the effect that cells that have been damaged to a certain extent, particularly at the DNA level, do not have the chance to proliferate and in case disseminate in the body. The cells once dead will then be extinguished by natural processes in the body and be replaced by "healthy" epithelial cells. Likewise, by means of blocking or modifying CD<sub>1d</sub> also an interaction with NKT is substantially prevented or altered, wherein the phenomenon of immune suppression during exposure to UV radiation will be essentially reduced or barred at all. Also, this condition is supposed to assist the organism's immune system to eradicate damaged cells, brought about by exposure to UV.

The substance capable of blocking and/or modifying the CD<sub>1d</sub> transmembrane molecule's activity may be any substance interfering with the endogenous biological function of CD<sub>1d</sub>, and in particular preventing or reducing association of CD<sub>1d</sub> with endogenous or exogenous lipids. The substances are obtainable by a process comprising the steps of (a) exposing epithelial cells to a substance of interest, (b) subjecting the epithelial cells to a stress situation, (c) determining the effect of said stress to said epithelial cells by screening for one or more of the following assays: (i) epithelial hyperplasia (H&E), (ii) epithelial proliferation (BrUd, PCNA), (iii) epithelial apoptosis, (iv) p53 mutation accumulation, (v) quantitative and qualitative assessment



of epithelial lipids, (vi) co-clustering patterns of apoptotic and non-apoptotic cell surface receptors, (vii) production of pro-inflammatory cytokines, (viii) production of immunomodulatory cytokines, (ix) markers of inflammation, (x) anti-apoptotic transcription factor activity (xi) markers of ageing, and (d) comparing the results obtained with a control. Such a control may e.g. be an assay, wherein the cells have been subjected to the same stress situation, wherein, however, no substance to be investigated had been added (negative control). Likewise a control may also be, including a substance with a known positive effect in the assay and determining the difference in effect achieved by the substance investigated and the known substance (positive control).

A substance is considered to be active in the context of this application, in case it prevents the negative effects of stress as detailed according to any of the above assays.

It will be appreciated that CD<sub>1d</sub> activity may be blocked and/or modified by substances acting on the genetic level or at the protein level.

Substances acting on the genetic level are compounds influencing, in particular preventing transcription or translation of the CD<sub>1d</sub> gene, such as polynucleotides anti-sense to at least a part of the CD<sub>1d</sub> gene or the CD<sub>1d</sub>-mRNA.

The terms oligonucleotide and polynucleotide, which are interchangeably used herein, include linear oligomers/polymers of natural or modified monomers or linkages, including desoxyribonucleosides, ribonucleosides,  $\alpha$ -anomeric forms thereof, polyamide nucleic acids, and the like, capable of specifically binding to the target nucleic acid by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, Hoogsteen or reverse Hoogsteen types of base pairing, or the like. Usually the monomers are linked by phosphodiester bonds or analogs thereof to form oligonucleotides ranging in size from a few monomeric units, e.g. 3-5, to several 100 or even thousands of monomeric units.

The (anti-)sense oligo-/polynucleotides may also contain pendent groups or moieties, to enhance specificity, nuclease resistance, delivery, or other property related to efficacy, such as e.g. cholesterol moieties, duplex intercalators such as acridine, poly-L-lysine, "end capping" with one or more nuclease-resistant linkage groups such as phosphorothioate, and the like. The corresponding oligonucleotide may be used for blocking transcription, RNA processing and/or

translation of the mRNA, Consequently, the oligonucleotide may comprise exon, but also intron sequences of the CD<sub>1d</sub>-target gene, as desired.

5 The nucleotide sequence of the human CD<sub>1d</sub> gene or mRNA is obtainable from NCBI (Accession numbers: AP002532 and NM\_001766, respectively). Based on his general knowledge and skill, the skilled person may select at least a portion of the coding region of the CD<sub>1d</sub> gene and design an appropriate anti-sense polynucleotide, that prevents transcription and/or translation of the CD<sub>1d</sub> gene. Likewise, also a part of the non-coding region of the CD<sub>1d</sub> gene may serve as an agent for preventing transcription or reducing the number of transcripts, respectively, of the CD<sub>1d</sub> gene. Here, in particular parts of the promotor region may serve as a  
10 template for preparing an antisense polynucleotide, but likewise transitions regions from introns and exons and vice versa. According to a preferred embodiment such a substance may be an DNA or a cRNA (RNA-interference).

Yet, apart from the CD<sub>1d</sub> gene being the target, also the activity of a number of regulatory molecules which control epithelial homeostasis such as ceramides and/or glucosylceramides,  
15 may be modified such, that they exert the desired effect on the CD<sub>1d</sub> molecule. To this end, the number of the glucosylceramide synthase transcripts may be reduced by designing an polynucleotide antisense to at least a part of the glucosylceramide synthase gene or glucosylceramide synthase mRNA, so that eventually the signal to epithelial cells to proliferate is turned down. The nucleotide sequence of the glucosylceramide synthase gene is disclosed in  
20 Ichikawa et al., PNAS 93 (1996), 4638-4643, which document is incorporated herein by way of reference. Likewise, non coding regions may serve as a template for the antisense polynucleotide, such as the promotor region and/or transitions from introns to exons and vice versa. According to a preferred embodiment such a substance may be a DNA or a cRNA (RNA-interference).

25 Apart from reducing the proliferation signal also the signal driving epithelial cells to apoptosis via the CD<sub>1d</sub> molecule may be enhanced. In this respect the number of corresponding transcripts may be increased, which may be effected by providing a higher number of polynucleotides encoding a sequence comprised by the sphingomyelinase or ceramide synthase gene and/or the sphingomyelinase or ceramide synthase mRNA.

Apart from the genetic level, the biological activity of the CD<sub>1d</sub> molecule may also be modified, in particular blocked at the protein level, in particular by any substance binding to the CD<sub>1d</sub> receptor on or in epithelial cells and blocking the endogenous biological functionality thereof.

5 According to a preferred embodiment the substance capable of modifying, in particular blocking biological CD<sub>1d</sub> function is a polypeptide or a peptide, in particular hydrophobic peptides, more preferably an antibody, or a part thereof, that binds to the CD<sub>1d</sub> receptor and blocks its biological function, such as the interaction with NKT. As parts thereof, in particular mini-antibodies are envisaged lacking the F<sub>c</sub>-part. According to an alternative embodiment the  
10 substance capable of blocking the biological CD<sub>1d</sub> function may also be a soluble CD<sub>1d</sub> receptor, that is, that part of the polypeptide lacking the region, anchoring the polypeptide in the membrane. The soluble CD<sub>1d</sub> receptor will scavenge the in vivo ligands that promote survival of the stressed cells, thus promoting apoptosis. In addition, binding of the natural killer cells to CD<sub>1d</sub> in vivo will be reduced, thus preventing activation of the T-cells and consequently  
15 inflammatory and/or immunosuppressive reactions.

According to a preferred embodiment the substance capable of blocking and/or modifying biological CD<sub>1d</sub> function is a lipid derived from a plant, microbe or animal, including a phospholipid, ganglioside, sphingolipid, glycosphingolipid, phosphatidylinositol phosphate, sterol, polyphenol, glyceride or fatty acid. These lipids may influence CD<sub>1d</sub> function by directly  
20 binding the CD<sub>1d</sub> molecule or indirectly by influencing CD<sub>1d</sub> gene expression.

According to an alternative embodiment the substance capable of blocking and/or modifying biological CD<sub>1d</sub> function is a ceramide, such as ceramide 8 or sphingosine phosphocholine or a ligand of a receptor belonging to the TNF-superfamily, in particular CD95/APO-1/Fas, which induces apoptosis thus interfering with the anti-apoptotic function of  
25 CD<sub>1d</sub>. In another embodiment the objective substance is an organic compound obtained by chemical synthesis.

It is well established that ceramide glycosylation, via glucosylceramide synthase, and the subsequent build up of glucosylceramides allows cellular escape from stress-induced programmed cell death, conferring cancer cell resistance of a variety of cancers including breast,  
30 skin, colon and epithelioid carcinomas, to cytotoxic anti-cancer agents. As CD<sub>1d</sub> can bind

glucosylceramide and is over-expressed by the same multi-drug-resistant cancer cells (e.g. squamous cell carcinoma), it is envisioned that the anti-apoptotic activity of CD<sub>1d</sub> regulates cancer cell resistance to cytotoxic drugs, possibly at the level of protein-glucosylceramide binding. Thus, in principle the substances of the present invention that block and/or modify  
5 endogenous CD<sub>1d</sub> function strongly decrease multi-drug resistance of a variety of cancers including skin, gut and breast cancers.

In principle, the substances of the present invention may also influence the bi-directional trafficking of CD<sub>1d</sub> to and from the membrane.

The substances may be included in any composition suitable for administering the  
10 substance to an individual, in particular a food composition, a cosmetic composition or a pharmaceutical composition.

The pharmaceutical compositions containing at least one of the substances capable of blocking or modifying the CD<sub>1d</sub> surface molecule according to the invention can be administered for prophylactic and/or therapeutic treatments. In therapeutic applications, compositions are  
15 administered to a patient already suffering from a disease, as described herein under, in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as "a therapeutically effective dose". Amounts effective for this will depend on the severity of the disease and the weight and general state of the patient.

20 In prophylactic applications, compositions containing at least one of the substances capable of blocking or modifying the CD<sub>1d</sub> surface molecule according to the invention are administered to a patient susceptible to or otherwise at risk of a particular disease. Such an amount is defined to be "a prophylactic effective dose". In this use, the precise amounts again depend on the patient's state of health and weight.

25 The compounds of the invention are preferably administered with a pharmaceutical acceptable carrier, the nature of the carrier differing with the mode of administration, for example parenteral, intravenous, oral and topical (including ophthalmic) routes.

The desired formulation can be made using a variety of excipients including, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium  
30 saccharin cellulose, magnesium carbonate. This composition may be a tablet, a capsule, a pill, a

solution, a suspension, a syrup, a dried oral supplement, a wet oral supplement, dry tube-feeding, wet tube-feeding etc. In order to control the drug release, sustained-release formulations can also be used.

5 The kind of the carrier/excipient and the amount thereof will depend on the nature of the substance and the mode of drug delivery and/or administration contemplated. E.g., for formulations containing weakly soluble antisense oligonucleotides, micro-emulsions may be employed, for example by using a non-ionic surfactant such as Tween 80 in an amount of about 0.04-0.05% (w/v), to increase solubility. Other components may include antioxidants, such as ascorbic acid, hydrophilic polymers, such as, monosaccharides, disaccharides, and other  
10 carbohydrates including cellulose or its derivatives, dextrans, chelating agents, such as EDTA, and like components well known to those in the pharmaceutical sciences. These various components utilized provide a variety of functions, including regulation of drug concentration, regulation of solubility, chemical stabilization, regulation of viscosity, absorption enhancement, regulation of pH, and the like. For example, in water soluble formulations the pharmaceutical  
15 composition preferably includes a buffer such as a phosphate buffer, or other organic acid salts, preferably at a pH of between about 7 and 8.

It will be appreciated that the skilled person will, based on his own knowledge select the appropriate components and galenic form to target the active compound to the tissue of interest, e.g. the colon, stomach, skin, kidney or liver, taking into account the route of administration  
20 which may be by way of injection, topical application, intranasal administration, administration by implanted or transdermal sustained release systems, and the like.

The objective substance may also be formulated in a cosmetic product, such as lotions, shampoos, creams, sun-screens, after-sun creams, sun-blocker, anti-ageing creams, ointments and/or anti-hair loss liquids. This proves in particular advantageous for essentially blocking CD<sub>1d</sub>  
25 function in the skin and to prevent the adverse effect of sun radiation, photo-ageing and exposure of the skin to free radicals. Thus, e.g. by providing a sun-screen containing in addition to a common agent, absorbing UV-light a substance as defined herein, a protection to the sun may be provided, which by far exceeds anything known so far. This feature is based in particular on the fact that the objective substance will penetrate the skin and exert its effect after having reached  
30 the target molecules. Since this effect will stay for a while, protection to the sun will even be

present in case the sun-screen has been rubbed off or has been washed off, as e.g. during sport etc. Yet, apart from sun-screens the objective substances may be included in common day-creams, lotions etc. to prevent negative effects of the daily environment, including pollution, oxidative stress etc. It will be appreciated that the present cosmetic products will contain a mixture of different ingredients known to the skilled person, ensuring a fast penetration of the objective substance into the skin and preventing degradation thereof during storage.

Another high important composition according to the present invention is food material. In our present society a great deal of food is ingested, such as sausages, salted or grilled meat etc., that contains preservatives, ingredients or substances, that are injurious to the gut. E.g. grilled meat contains aliphatic and aromatic compounds known to be cancerogenic. Also preservatives, that kill micro-organisms contained in food material (e.g. sausages) by manipulating their DNA, will exert a similar effect to cells of the gut. In fact, the number of intestinal cancer is steadily increasing in our society, which may be attributed at least in part to the type of food taken by humans.

Consequently, the present invention provides a food composition that prevents the onset and/or development of such gut disorders, such as a composition selected from the group consisting of milk, or fermented milk products, such as e.g. yogurt, curd, cheese, milk based fermented products, ice-creams, milk based powders, infant formulae, cereal products and fermented cereal based products, mineral water, chocolate or pet food containing at least a substance capable of essentially blocking and/or modifying CD<sub>1d</sub> function. Since the objective compound will be contained in a food material in amounts, that do not affect the original taste thereof, the consumer will not notice any change in the product, but will experience the beneficial effects thereof, namely a protective or even curing effect. Once the food material has been ingested the objective substances will arrive at the target cells, which may be epithelial cells of the gut, i.e. of the stomach or the intestine, and will bind to the CD<sub>1d</sub> receptor and exert its activity. As a consequence, cells, that are already damaged will preferably go to apoptosis instead of being maintained in said damaged form.

Since epithelial cells bearing CD<sub>1d</sub> have been found in a number of organs, such as the liver, the small intestine, the colon, the kidney, the prostate, the uterus, the pancreas, breast, skin and conjunctiva, the choice of the composition as detailed above will, by and large depend on the

target tissue. As will be understood, for skin a cosmetic product might be the composition of choice, while in case of delivering the objective substance directly to the gut or the colon, a food product may be first choice. However, a food product may also be suitable for delivering the objective substance or substances to other organs, such as the kidney or the liver, which will depend on the stability of the substance in the body and its capacity of being absorbed by the body in the gut. Since food is a daily ingested material such a product offers a great variety of different possibilities. Yet, in case the objective substance is prone to degradation in the gut a pharmaceutical composition may be selected, providing e.g. encapsulation or other galenic forms to deliver the objective substance to the target tissue/to target cells.

It will be understood that the concept of the present invention may likewise be applied as an adjuvant therapy assisting in presently used medications. In this respect the pharmaceutical composition of the present invention may be administered together with e.g. cytostatika so as to prevent escape of the tumor treated from the treatment, which sometimes occurs in long term treatments of certain tumors or to assist in killing residual cancer cells not captured with the pharmaceutical regimen. Since the substance(s) of the present invention may easily be administered together with food material special clinical food may be applied containing a high amount of the objective substances. Also melanoma may be directly treated with an antibody medication against melanoma together with a pharmaceutical composition or a cosmetic product as described herein. It will be clear that on reading the present specification together with the appending claims the skilled person will envisage a variety of different alternatives to the specific embodiments mentioned herein.

In principle, the substances according to the present invention may be used for the treatment and/ or prevention of damages in epithelial tissues, such as e.g. in the skin, gut, eye, lung, liver, prostate, breast, kidney and/or in the uterus, which are produced by a stress situation, e.g. by means of a chemical, biological or a physical stress, e.g. by exposure to oxidants or carcinogens, exposure to bacteria, viruses, fungi, lipids derived from surrounding cells and/or microbes, or exposure to UV-irradiation. Likewise, the substances may be utilized for preventing and/or treating hair loss.

Consequently, the substances and/or compositions according to the present invention may be utilized for treating and or preventing damages of the skin, in particular actinic and ageing

damages of the skin such as dryness, actinic keratoses, irregular pigmentation (notably comprising freckling, lentigines, guttate hypomelanosis and persistent hyperpigmentation), wrinckling (notably comprising fine surface lines and deep furrows), stellate pseudoscars, elastosis, inelasticity, telangiectasia, venous lakes, purpura, comedones, sebaceous hyperplasia, acrochordon, cherry angiogema, seborrhea keratosis, lentigo, basal cell carcinoma and squamous cell carcinoma, skin burning and/or blistering, cataract formation, epidermal hyperplasia, inflammation, immune suppression, and cancer, e.g. non-melanoma and melanoma skin cancers.

In order to arrive at additional substances having the above characteristics the present invention also provides a method for screening for such substances. In this method epithelial cells are utilized that may be in the form of a primary culture, i.e. directly derived from an individual or in the form of a cell line. For carrying out the method a cell culture is particularly preferred, since it allows for the continuous supply of epithelial cells during the experiments. Care must be taken that the cell culture of epithelial cells used exhibit the same phenotypic traits as do cells of a primary culture or epithelial cells directly obtained from a tissue sample. It will be understood that the person skilled in the art will select the starting material depending on the assay. Hence, if a first round assay is to be carried out a cell culture design seems to be most appropriate, while in case for further rounds, i.e. assessing the activity of potential candidates, the tissue or even the animal model seems to be more appropriate.

The epithelial cells are exposed to a substance of interest for a time period sufficient to ensure a contact of the substance with the cells. In a next step the epithelial cells are exposed to a stress situation, which may be effected e.g. by irradiating the cells with different dosages of UV light, or adding hydrogen peroxide or toxic chemicals to the cell culture. However, the type of stress is not critical as long as the cells are challenged to initiate processes, normally started under stress situations, such as e.g. the production of pro-inflammatory cytokines e.g. IFN- $\gamma$ , TNF- $\alpha$ , IL-1, IL-6, IL-8, apoptosis, altered lipid metabolism, increased production of p53, altered cell signaling as a result of altered patterns of cell surface receptor co-clustering, NF- $\kappa$ B activation, AP1 activation, showing hyperproliferation (anti-apoptosis), altered barrier function etc. It will be understood that also more than one substance may be tested at the same time, that is a cocktail of one or more substances, which might prove beneficial for the second or further round of assaying.



In a next step the effect of said stress on the epithelial cells is determined by assessing one or more of the following features, for example: epithelial proliferation (PCNA: Ouhtit et al., American Journal of Pathology [2000], 156: 201-207; BrUd: Lu Y-P et al., Cancer Research [1999], 59: 4591-4602 ); epithelial apoptosis (Tunel Assay; modification of protocol outlined by  
5 Ouhtit et al., American Journal of Pathology [2000], 156: 201-207); p53 mutation accumulation (Allele-specific polymerase chain reaction [AS-PCR] and single-strand conformation polymorphism [SSCP], Ananthaswamy et al., Nature Medicine [1997], 3: 510-514); production of pro-inflammatory and immuno-modulatory cytokines (e.g. TNF- $\alpha$ , PGE-2, IL-1, IL-6, IL-8, IL-4, IL-10, Platelet Activating Factor, TGF $\beta$ ); markers of inflammation (e.g. COX-2, iNos); and  
10 anti-apoptotic transcription factor (including AP-1, NFkappaB) activity by TaqMan Real-time RT-PCR, ELISA, and Immunohistochemistry; qualitative and quantitative assessment of phospholipids, glycosphingolipid and sphingolipid content (Electron-Spray Tandem Mass Spectrometry); analysis of co-clustering patterns of epithelial cell surface receptor molecules including cytokine receptors (e.g. IL-6), molecules of the TNF-superfamily of receptors (e.g.  
15 CD95/APO-1/Fas) and growth regulating receptors (e.g. EGF, Insulin) by fluorescence resonance electron transfer analysis (FRET); markers of ageing, e.g. elastases, collagenases, metalloproteinases, gelatinase, stromelysins, telomerase.

The results obtained are then compared with a control, which may simply be an assay, wherein the same type of cells are exposed to the same stress conditions with the proviso, that no  
20 compound to be assessed for its CD<sub>1d</sub> blocking capacity is provided. As for the animal model a positive control is represented by a CD<sub>1d</sub><sup>-/-</sup> animal, wherein CD<sub>1d</sub> activity is lacking at all.

The following examples illustrate the invention in more detail without restricting the same thereto.

### **Example 1**

#### **Generation of CD<sub>1d</sub> mutant mice**

25 Mouse CD<sub>1d</sub> is encoded by two genes, CD<sub>1d1</sub> and CD<sub>1d2</sub>, that share a high degree of nucleotide sequence identity (Bradbury et al., EMBO J., 7 (1988), 3081-3086). The product of the CD<sub>1d1</sub> gene is recognized by all anti-CD<sub>1</sub> antibodies that have been described, whereas surface expression of the CD<sub>1d2</sub> product has not yet been demonstrated. In addition, the predicted  
30  $\alpha$ 2 domain of the CD<sub>1d2</sub> gene product lacks an intra-domain disulfide bond that is found in the

$\alpha 2$  domain of all published classic and non-classic MHC class I molecules (Bradbury, supra). This disulphide bond is thought to be critical for the folding of the antigen-binding groove. Thus, the CD<sub>1d2</sub> gene may not encode a functional antigen-presenting molecule, and all functions previously attributed to mouse CD<sub>1</sub> may be effected by the product of the CD<sub>1d1</sub> gene. For this reason, it was decided to introduce a targeted mutation into the CD<sub>1d1</sub> gene, while leaving CD<sub>1d2</sub> intact.

The CD<sub>1d</sub> gene was isolated from a strain 129/Sv phage library with a probe generated by polymerase chain reaction. The targeting construct was prepared using a 2.8 kb Apal fragment containing the 5' region of the CD<sub>1d</sub> gene, a 3.2 kb BamHI-NotI fragment containing the 3' region of the CD<sub>1d</sub> gene (the NotI site in this fragment comes from the pBluescript vector into which phage DNA was initially subcloned), a neomycin resistance gene (neo), and the pBluescript plasmid (Stratagene). This construct was designed to delete a fragment of about 200 bp from the exon encoding the  $\alpha 2$  domain of CD1d1. The strain 129/Sv-derived embryonic stem (ES) cell line TL1 was transfected with the NotI-linearized targeting vector. G418-resistant colonies were selected and isolated as described in Van Kaer *et al.*, Cell 71 (1992), 1205-1214. Genomic DNA from individual clones was digested with EcoRI and hybridized with a 2.3 kb ClaI-EcoRI probe from the 5' end of the CD1d1 gene. Recombination was confirmed by digestion with KpnI and hybridization with a 700 bp BamHI-EcoRI probe from the 3' end of the CD<sub>1d1</sub> gene. Chimeric mice were mated with C57BL/6 mice to score for germline transmission, and heterozygous mutant mice were intercrossed to obtain (C57BL/6x129/Sv) F2 homozygous mutants. Mice were typed for their CD1d1 status by genomic southern blotting with the 5' probe. Mutant mice were healthy and bred normally.

Because the ES cells and mouse strain used to generate mutant animals differ in their TL status (129/Sv is a TL+ strain and C57BL/6 is a TL- strain) all mice used in this study were genotyped for TL. To type mice for their TL status, tail DNA was digested with BglII and hybridized with a TL-specific probe that detects a polymorphism between strains 129/Sv (TL+) and C57BL/6 (TL-) (Pontarotti *et al.*, Proc. Natl. Acad. Sci. USA 83 (1986), 1782-1786). This probe was generated by polymerase chain reaction using a set of primers designed on the basis of published sequences (Pontarotti, supra):

5'-TATACAGAGCTCCGTAGGAC-3' ; and

5'-AGTTGTCTGCAGCCACGAAC-3'.

The CD<sub>1d</sub> mutant and wild-type mice were housed in a specific-pathogen-free barrier animal facility, accredited by the American Association for Accreditation of Laboratory Animal Care (AAALAC). Animals were used between 12-16 weeks of age at the start of the experiments. They were housed in filter-protected cages with a 12h light-dark controlled cycle, and provided with autoclaved NIH open formula mouse chow and water ad libidum. The institutional Animal Care and Use Committee approved all procedures. Within each experiment all mice were aged- and sex-matched.

It is underlined that other genetic backgrounds can be used for creating a CD<sub>1d</sub> mutant mouse, such as Balb/C genetic background.

### Example 2

#### **UV Irradiation of mice**

A bank of five Philips TL-40W/12 sunlamps (Philips, The Netherlands) was used to irradiate the mice. These lamps emit a spectrum from 270 to 400 nm; 54% of the irradiation was within the UVB range (280-315 nm) of the solar spectrum, with 45% being in the UVA (315-400nm) region and less than 1% in the UV-C (240-280 nm) range. The irradiance of the five bulbs averaged 10 W/m<sup>2</sup>, as measured by a UVB PMA research radiometer.

The dorsal hair of the mice was removed with electric clippers and the mice were placed into a plexiglass box separated into individual compartments by Plexiglas dividers and covered with a wire top which decreased the incident dose by 14%. For each UV-irradiation, the box was placed each time in the same position under the lamps to compensate for the uneven distribution of energy along the length of the bulbs. The mice were exposed once or twice to an incident dose of 86 mJ/cm<sup>2</sup> UVB from five Philips TL-40W/12 sunlamps. Mice were exposed to a second dose of UVB radiation 96h after the first exposure. All mice were analyzed for signs of skin damage 24, 48, 72 and 96 h after their last UVB exposure.

Visually, a clear difference in the degree of skin damage was observed between wild-type and CD1d knockout mice following UVB-irradiation of their shaved dorsums. Whilst clear and significant skin damage (burning, skin lesions) was exhibited by UV-irradiated wild-type mice, no obvious signs of skin damage were detected in UV-irradiated CD1d knockout mice.

### **Example 3**

#### **Measurement of apoptosis in epidermis**

Apoptotic cell death was detected using the DeadEnd™ Fluorometric TUNEL System (Promega) which measures the fragmented DNA of apoptotic cells by catalytically incorporating fluorescein-12-dUTP at 3' -OH DNA ends using the enzyme Terminal Deoxynucleotidyl Transferase (TdT). TdT forms a polymeric tail using the principle of the TUNEL assay. Briefly, formaline fixed paraffin embedded tissue sections on slides were deparaffinized twice in fresh xylene for 5 min at room temperature. They were washed in 100% ethanol for 5 min and then rehydrated sequentially by immersing the sections through graded (100%, 95%, 85%, 70%, 50%) ethanol washes for 3 min. Afterwards, the sections were immersed in 0.85% NaCl for 5min, washed in PBS and then fixed in 4% paraformaldehyde for 15 min followed by two washes in PBS. After removing residual fluid from the sections by tapping, each tissue section was covered with 20µg/ml proteinase K (Sigma) for 8-10 min at room temperature. After proteinase K treatment, tissue sections were rinsed in PBS and then fixed by immersing in 4% paraformaldehyde for 5 min. This was followed by a wash in PBS, removal of residual fluid by tapping and incubation of the sections in equilibrium buffer (Promega) for 5-10 min. After equilibration, the sections were incubated in a humidified chamber with TdT enzyme for 1 h at 37°C. Sections were soaked in stop buffer (SSC; Promega) for 15 min to terminate the reactions and then rinsed in three changes of PBS. After rinsing, sections were stained with propidium iodide solution freshly diluted to 1µg/ml in PBS for 15 min in the dark. They were then washed three times in deionized water for 5 min, and afterwards, excess fluid wiped off the area surrounding the cells. The sections were then immediately examined under a fluorescence microscope.

At 2, 6, 24, 48, 72 and 96h after UV exposure (acute/chronic) a TUNEL Assay (modification of protocol outlined by Ouhtit et al., American Journal of Pathology [2000], 156: 201-207), of the skin taken from CD1d<sup>-/-</sup> and wild-type mice was carried out. The results revealed that epidermal cells within the skin of CD1d<sup>-/-</sup> mice were undergoing a high degree of apoptosis compared to wild-type mice. In contrast, in wild-type skin the epidermal cells were undergoing significantly less apoptosis.

#### **Example 4**

##### **Measurement of Epidermal Hyperplasia**

Dorsal skin biopsies were fixed overnight in 4% paraformaldehyde and paraffin embedded. Sections were stained with hematoxylin and eosin (H&E) and viewed by light microscopy.

Following UVB exposure,  $CD_{1d}^{-/-}$  mice exhibited significantly reduced epidermal hyperplasia 48h after the last UVB treatment compared to UV-irradiated wild-type mice.

#### **Example 5**

##### **Gene profiling**

In order to elucidate  $CD_{1d}$  function a gene profiling assay comparing wild-type and  $CD_{1d}$  knockout mouse gene expression had been performed.

Skin tissue was extracted from 5 individual wild-type and  $CD_{1d}$  knockout mice and extracted separately using Trizol kit (Invitrogen AG, Basel, Switzerland) and then Qiagen RNeasy mini-kits (Basel Switzerland) according to manufacturer instructions with DNase I treatment to remove any genomic DNA contamination. RNA samples were quantified by OD then analyzed via dynamic gel electrophoresis with the Agilent Bioanalyser for intact 28S and 18S rRNA (All 28 / 18 ratio's were between 1.6 and 2.0). Study samples were judged to contain sufficient amounts of high-quality RNA for hybridization to GeneChips. As another quality control measure, prior to hybridization with Affymetrix GeneChips (Affymetrix, Inc., Santa Clara, CA), we confirmed that all samples gave strong signals for pre-selected genes, using Affymetrix test chips (Test chip 5' / 3' ratios were less than 3.0).

For skin, 10  $\mu$ g total RNA was the starting material for all individual mouse samples. In general, total RNA was converted to biotinylated cRNA, hybridized in the Affymetrix probe array cartridge, stained, and then quantified. First and second strand cDNA synthesis was performed using the SuperScript Choice System (Invitrogen AG, Basel, Switzerland), according to manufacturer instructions, but using an oligo-dT primer containing a T7 RNA polymerase binding site. Labeled cRNA was prepared with the RNA Transcript Labeling kit (Enzo Biochem Inc., NY). Biotinylated CTP and UTP were used together with unlabeled NTPs in the reaction, and unincorporated nucleotides were removed with Nucleospin columns (Macherey-Nagel, Düren, Germany).

cRNA (20 µg) was fragmented at 94 °C for 35 min in buffer containing 200 mM Tris-acetate pH 8.1, 500mM KOAc, 150 mM MgOAc. Prior to hybridization, fragmented cRNA in hybridization mix ( Buffer containing 100 mM MES, 1M NaCl, 20 mM EDTA, 0.01% Tween 20, 0.5 ng/µl BSA, 0.1 ng/µl herring sperm and Affymetrix controls ), was heated to 95 °C for 5 min, cooled to 45 °C and loaded onto an Affymetrix probe array cartridge. The probe array was incubated for 16 h at 45 °C at constant rotation (60 rpm), then exposed to Affymetrix washing and staining protocol.

This protocol included:

- one wash with non-stringent buffer ( 6X SSPE, 0.01% Tween 20, 0,005% antifoam )
- one wash with stringent buffer ( 100 mM MES, 0.1 M NaCl, 0.01 % tween 20 )
- First stain with 0.01 mg/ml streptavidin-phycoerythrin conjugate (Molecular Probes) in buffer containing 100 mM MES, 1M NaCl, 0.05% Tween 20, 4 mg/ml of BSA.
- one wash with non-stringent buffer ( 6X SSPE, 0.01% Tween 20, 0,005% antifoam )
- Second stain with 3 µg/ml of biotinylated anti-streptavidin + 0.2 mg/ml of IgG in buffer containing 100 mM MES, 1M NaCl, 0.05% Tween 20, 4 mg/ml of BSA.
- Third stain with 0.01 mg/ml streptavidin-phycoerythrin conjugate (Molecular Probes) in buffer containing 100 mM MES, 1M NaCl, 0.05% Tween 20, 4 mg/ml of BSA.
- one wash with non-stringent buffer ( 6X SSPE, 0.01% Tween 20, 0,005% antifoam )

A mathematical method was developed and applied to the raw GeneChip data for the selection of differentially regulated genes. This method moves beyond setting a single fold change cut-off by considering the standard deviation (SD) in the context of absolute expression, or absolute difference intensity (ADI).

The method include the following steps: (A) data processing by the commercially available "MAS5" Affymetrix program (Santa Clara, CA, USA) and rescaling, (B) logarithmic transformation to distribution normality of the rescaled data, (C) multiple hypotheses (one per gene) analysis of variance (ANOVA) testing, (D) the determination of the robust mean within condition SD (equation 1), within bins of 200 genes ordered by mean ADI levels, to determine a significance limit SD between condition, named the REGExpress function (equation 2 from Genome Biology 2001 2(12): preprint0009.1-0009.31); and (E) subsequent ranking of genes by

the p value of the REGExpress and ANOVA, to help focus at effect importance. The selection is made with the p value resulting from multiple hypotheses (one per gene) ANOVA testing and/or with the p value resulting from REGExpress.

5 Probe arrays were scanned at 488 nm using an Argon-ion Laser (made for Affymetrix by Agilent). Readings from the quantitative scanning were analyzed with Affymetrix Gene Expression Analysis Software.

10 The findings are summarized in the tables I to III below. The fold increase (+) or decrease (-) is the statistically significant relative fold increase or decrease of a gene expressed in CD1d knockout mice compared to the same gene expressed in wild-type mice. It becomes clearly evident that blocking CD1d upregulates genes controlling hair follicle development, and down-regulates genes involved in inflammation and cancer development.

Table I  
Genes which regulate hair follicle development

Gene Name	Fold increase/decrease	Mean Wt	Mean CD1d -/-	Biological Function
<b>mmu-crystalline</b>	+27.0	0.922	4.251	thyroid binding protein regulating hair follicle development
<b>PPatched homolog 2</b>	+2.763	3.810	4.826	hair follicle development

15

**Table II**  
**Genes which regulate inflammation**

Gene Name	Fold increase/decrease	Mean Wt	Mean CD1d -/-	Biological Function	Disease Association
TGF beta activated Kinase	+1.743	3.630	4.186	Signalling molecule of the p38-MAPKinase and the Stress activated protein Kinase (SAPK) pathways.	
Rel-A(NfKappaB)	-0.735	7.350	7.043	anti-apoptotic, induction of inflammatory cytokines.	inflammatory disorders
Cytochrome beta	-0.738	6.829	6.525	superoxide generation	
Plasminogen activator inhibitor (PAI-1)	- 0.357	3.906	2.875	Serine protease inhibitor. Regulates fibrolysis.	inflammatory disorders
MRP14	- 0.202	3.943	2.344	Ca <sup>++</sup> dependent regulatory protein in inflammatory responses.	acute and chronic inflammatory responses e.g. Psoriasis
Mast cell protease	- 0.661	6.427	6.014	proteolysis and peptidolysis.	inflammation
P-Selectin	- 0.685	6.439	6.060	Cell adhesion	inflammation
TFII-1	+1.373	5.707	6.024	Transcription factor which regulates c-Fos activity	
Interleukin-6	- 0.268	1.882	0.565	cytokine: multi-functional	inflammation

5

**Table III**  
**Genes which regulate cancer growth/development:**

Gene Name	Fold increase/decrease	Mean Wt	Mean CD1d -/-	Biological Function	Disease Association
v-Rel (NfKappaB)	-0.735	7.350	7.043	oncogenic-transforms cells	cancer
Plasminogen activator inhibitor (PAI-1)	- 0.357	3.906	2.875	serine protease inhibitor	metastatic tumors
P-Selectin	- 0.685	6.439	6.060	adherence	facilitates tumor metastasis.
Cathepsin S	- 0.697	7.545	7.184	cysteine protease	malignancy
Proliferin	- 0.234	1.870	0.419	regulates angiogenesis	mouse fibrosarcomas
Interleukin-6	- 0.268	1.882	0.565		secreted by basal cell carcinomas and malignant melanomas.
CSF-1 receptor	- 0.750	7.196	6.909	Growth factor regulating cell proliferation.	Cancer



### **Example 6**

Evaluation of the inflammatory response induced by a single topical administration of TPA

Phorbol-12-myristate-13-acetate (TPA) provided by Sigma Aldrich (L'Isle d'Abeau  
5 Chesnes BP701, 38297 Saint Quentin Fallavier, France) is dissolved in acetone at the dose of 0.01 % (W/V) and 20 µl of the solution is applied topically onto the internal face of the right ear of CD<sub>1d</sub><sup>-/-</sup> mice or wild-type mice in order to induce an acute inflammatory response.

The animals are maintained in individual cages with a standard pellet diet in an animal room with a 12-hour light-dark cycle. The facilities provide a filtered air with a temperature of  
10 22 +/- 2 °C and a relative humidity of 55 +/- 10 %.

The inflammatory response is quantified 6 hours, 24 hours and 48 hours after application by measuring the ear oedema using a micrometer (« oditest » provided by Kroeplin GmbH, Postfach 1255 D36372 Schlüchtern, Germany).

The oedema is calculated as follows:

15 (oedema = ear thickness of the treated group – ear thickness of the acetone group).

The mean value of CD<sub>1d</sub><sup>-/-</sup> group is compared to the mean value of the wild-type group using the Student's t-test.

### **Example 7**

20 Evaluation of the inflammatory response induced by a single topical administration of arachidonic acid

Arachidonic acid (5-8-11-eicosatetraenoic acid) provided by Sigma Aldrich (L'Isle d'Abeau Chesnes BP701, 38297 Saint Quentin Fallavier, France) is dissolved in acetone at the concentration of 140nM and 25 µl of the solution is applied topically onto the internal face of the right ear of CD<sub>1d</sub><sup>-/-</sup> mice or wild-type mice in order to induce an acute inflammatory response.

25 The animals are maintained in individual cages with a standard pellet diet in an animal room with a 12-hour light-dark cycle. The facilities provide a filtered air with a temperature of 22 +/- 2 °C and a relative humidity of 55 +/- 10 %.

The inflammatory response is quantified 1 hour, 2 hours, and 4 hours after application by measuring the ear oedema using a micrometer (« oditest » provided by Kroeplin GmbH, Postfach  
30 1255 D36372 Schlüchtern, Germany).

The oedema is calculated as follows:

(oedema = ear thickness of the treated group – ear thickness of the acetone group).

The mean value of  $CD_{1d}^{-/-}$  group is compared to the mean value of the wild-type group using the Student's t-test.

5      **Example 8**

Evaluation of the DTH (delayed-type hypersensitivity) reaction induced by oxazolone

Oxazolone (4-ethoxymethylene-2-phenyl-oxazol-5-one) provided by Sigma Aldrich (L'Isle d'Abeau Chesnes BP701, 38297 Saint Quentin Fallavier, France) is dissolved in acetone at the concentration of 1% (W/V) and 50 µl of the solution is applied once daily for 4 days on the abdominal skin of shaved  $CD_{1d}^{-/-}$  mice or shaved wild-type mice.

4 days later the animals are challenged by a single administration (20µl) onto the internal face of the right ear of oxazolone dissolved in acetone at the dose of 0.3%. The post-challenge response is quantified 24 hours and 48 hours after application by measuring the ear oedema using a micrometer (« oditest » provided by Kroeplin GmbH, Postfach 1255 D36372 Schlüchtern, Germany).

The oedema is calculated as follow :

(oedema = ear thickness of the treated group – ear thickness of the acetone group).

The mean value of  $CD_{1d}^{-/-}$  group is compared to the mean value of the wild-type group using the Student's t-test.

20      **Example 9**

Evaluation of skin damages induced by UV irradiation using a solar simulator

A solar simulator (Oriel 81050) equipped with an UVC filter is used to irradiate  $CD_{1d}^{-/-}$  mice or wild-type mice.

Irradiation: UVB + UVA doses and to be precised

25      Effect on epidermis: SBC counts, epidermal hyperplasia measurement

Effect on the dermis: MMP1 and MMP3 expression with immuno-histochemical methods

**Example 10**

Regulation of  $CD_{1d}$  gene transcription by UV radiation and role of  $CD_{1d}$  in regulating UV-induced COX-2 and TNF-α gene transcription

## MICE

Specific pathogen-free male outbred 129/C57BL/6 wild-type and 129/C57BL/6 CD1<sub>a</sub> knockout mice were obtained from L. Van Kaer, Vanderbilt University Medical Center (Nashville, TN, USA). The animals were maintained in facilities in accordance with current Swiss regulations and standards. They were housed in filter-protected cages, and ambient lighting was controlled to provide 12 h light/12 h dark cycles. Autoclaved open-formula mouse chow and water were provided ad libitum. All animal procedures were reviewed and approved by the Institutional Animal care and Use Committee. Within each experiment all the mice were matched for age and sex. The mice were 16 weeks at the start of each experiment.

## UV LIGHT SOURCE

The UVB source was a bank of five Philips TL-40W/12 sunlamps (Philips, The Netherlands). These lamps emit a spectrum from 270 to 400 nm; 54% of the irradiation was within the UVB range (280-315 nm) of the solar spectrum, 45% in the UVA (315-400nm) region and less than 1% in the UV-C (240-280 nm) range. The irradiance of the five bulbs averaged 10 W/m<sup>2</sup>, as measured by a UVB PMA research radiometer. Solar simulated light (UVA + UVB) was produced by a 1000W exon UV solar simulator (Solar Light Company, PA, USA) equipped with a WG-320 atmospheric attenuation filter (1mm thick), a visible/infrared band pass blocking filter (UG-5; 5mm thick), and a dichroic mirror to further reduce visible and infrared energy.

## UV IRRADIATION OF MICE

The dorsal hair of the mice was removed with electric clippers. For mice being exposed to UVB radiation they were placed into a Plexiglass box separated into individual compartments by Plexiglass dividers and covered with a wire top which decreased the incident dose by 14%. For each UVB-irradiation, the box was placed each time in the same position under the lamps to compensate for the uneven distribution of energy along the length of the bulbs. For mice being exposed to solar UV radiation (UVA + UVB) the mice were anaesthetized to immobilize them prior to being exposed to the beam of the solar simulator. The mice were exposed once to an incident dose of 86, 215 or 430mJ/cm<sup>2</sup> UVB from five Philips TL-40W/12 sunlamps. Mice exposed to solar light (UVA + UVB) were exposed once to an incident dose of 1680 (1 min), 16,800 (10 min) or 33,600mJ/cm<sup>2</sup> (20 min) solar radiation.

## UV IRRADIATION OF KERATINOCYTE CELL CULTURES

Confluent cultures of keratinocytes grown in sterile 6-well plates (Corning, Netherlands) were submitted to a single dose ( $5700\text{mJ}/\text{cm}^2$ ) of solar UV irradiation. Treatment was performed without plastic lids after having removed medium and replaced it by sterile HBSS. Control  
5 cultures were not irradiated. After UV exposure, HBSS was removed and medium put back on cultures. The cells were incubated at  $37^\circ\text{C}$  with 5%  $\text{CO}_2$  and at various time points thereafter harvested for RNA.

## IMMUNOSTAINING OF MOUSE TISSUE

Biopsies of wild-type mouse skin were fixed in formaline before being embedded in  
10 paraffin. Cross sections ( $5\mu\text{m}$  thick) of paraffin embedded tissues were made, deparaffinized by gentle heating, de-hydrated and rehydrated using the following procedure: 2 times for 3 min in Xylol, 3 min in Ethanol 100%, 3 min in Ethanol 95%, 3 min in Ethanol 80% and 3 min in PBS 1X. Fresh skin was also embedded in Tissue-Tek (4583, Sakura Finetek, Torrance, USA) and frozen in liquid nitrogen. The sections were then rehydrated in PBS 1X for few minutes. Sections  
15 were stained using the anti-mouse CD1d 1H1 primary mAb and developed using the mouse Histostain-plus kit (ZYMED Laboratories Inc., San Francisco, USA).

## EXTRACTION OF TOTAL RNA FROM SKIN OR CELL LYSATES

Treated and control cultures of human keratinocytes grown in 6-well plates were placed on ice and washed twice using PBS 1X at  $4^\circ\text{C}$ . Cell lysate was obtained by scraping the cells in  
20  $350\mu\text{l}$  of lysis buffer RLT (74104, Qiagen AG, Basel, Switzerland) supplemented with 1% of  $\beta$ -mercaptoethanol and by briefly vortexing them. QIAshredder columns (79656, Qiagen AG, Basel, Switzerland) were used to homogenize cell extracts by centrifugation at  $13,000\times g$  for 2 min. Total RNA was then prepared using RNeasy kits (74104, Qiagen AG, Basel, Switzerland) according to the manufacturer's protocols. Genomic DNA contamination was removed with on-  
25 column DNase digestion using a RNase-free DNase Set (79254, Qiagen AG, Basel, Switzerland). Skin samples of  $1\text{cm}\times 1\text{cm}$  were cut into small pieces and homogenized in 1ml of TRIZOL Reagent (15596-026, Invitrogen AG, Basel, Switzerland) using a rotor-stator homogenizer (Polytron, Kinematica, Luzern, Switzerland). The supernatant obtained after centrifugation at  $12,000\times g$  was recovered in a fresh tube and incubated for 5min at room  
30 temperature.  $0.2\text{ml}$  of chloroform was added to the tube, which was vigorously shaken for 15sec

and incubated at room temperature for 2-3min. Samples were centrifuged at 12,000xg for 15min at 4°C. The upper aqueous phase was transferred to a fresh tube and total RNA precipitated using 0.5ml of isopropyl alcohol for 10min at room temperature. The RNA pellet obtained by centrifugation at 12,000xg for 10min at 4°C was washed with 1ml of 75% EtOH followed by centrifugation at 7,500xg for 5min at 4°C. The RNA pellet was finally dried at room temperature and dissolved in 40µl of RNase free water by incubating the samples 10min at 55-60°C. Possible DNA contamination was removed with on-column DNase digestion using a RNase-free DNase Set.

#### SEMI-QUANTITATIVE RT-PCR

##### A. Reverse transcription-polymerase chain reaction and PCR reaction

5µg of total RNA were reverse transcribed by oligo-dT priming to first strand cDNA using the Superscript First-Strand Synthesis System for RT-PCR (11904-018, Invitrogen AG, Basel, Switzerland) according to the manufacturer's instructions. PCR of cDNA was performed to either detect specific expression of a single gene (single PCR) or multiple genes (Multiple gene PCR). For single PCR, 48µl of PCR master mix containing 5µl PCR Buffer, 3µl 25mM MgCl<sub>2</sub>, 1µl 10mM dNTPs, 0.5µl 50µM of both sense and anti-sense oligonucleotides, 3µl DMSO, 34.5µl of water and 0.5µl of 5U/µl Taq DNA Polymerase was added to 2µl of cDNA. All the reagents were purchased from Invitrogen (15558-026 and 18427-013, Basel, Switzerland). The number of cycles and the annealing temperature applied to amplify cDNA samples were specific to each gene tested, one cycle consisting of 30s at 94°C, 30s at x°C and 30s at 72°C, each amplification being preceded by 2min at 94°C and finished by 3min at 72°C. Kit MP-70211 (Maxim Biotechnologies, San Francisco, USA) for multiple gene PCR of genes implicated in apoptosis and inflammation were used as instructed. Prior to using each kit, the condition for running multiple reverse and forward primers at the same time to detect multiple genes was determined. The conditions for using kit MP-70211 which contained primers for detecting TNF-α and COX-2 genes, were as follows: 96°C for 1min and 60°C for 4 min (cycles 2x); 94°C for 1min and 60°C for 2 min (cycles 29x); 70°C for 10 min (cycle 1x) and 25°C soak. The DNA sequence of the reverse and forward primers used the MPCR kit for detecting multiple genes under one set of conditions were proprietary and thus are not described in this report.

## Primer Sequences and Number of Cycles of Amplification

### Human:

Gene	Primer	Sequence (5'- 3')	Annealing temper.	No. of cycles	Product Size
GAPDH	sense	AAT CCC ATC ACC ATC TTC CA	52	16	558
	antisense	GTC ATC ATA TTT GGC AGG TT			
CD1d	sense	GCT CAA CCA GGA CAA GTG GAC GAG	66	27	452
	antisense	AGG AAC AGC AAG CAC GCC AGG ACT			

### 5 Mouse:

Gene	Primer	Sequence (5'- 3')	Annealing temper.	No. of cycles	Product Size
GAPDH	sense	TTC ACC ACC ATG GAG AAG GC	60	22	236
	antisense	GGC ATG GAC TGT GGT CAT GA			
CD1d.1	sense	ACG TCC TGG CAG ACA GTC CCA GG	60	24	706
	antisense	TTA ATG TTG AAA AGA GCG TAC TGG C			

### B. Relative Quantification of mRNA levels

Amplification of the genes was analyzed by loading 10µl of the PCR products on a 3% agarose gel which was run in a 1XTAE buffer containing 2% Ethidium Bromide at 150V for 30min. The PCR products were visualized as fluorescent bands under UV light. Gels were scanned using a Kodac DC 120 Camera and fluorescence intensity of the bands was quantified using the Software Scion Image β 4.02 Win (Scion Corporation, Maryland, USA).

While studies of CD1d proteins in the murine system suggest a widespread and constitutive expression on many hematopoietic cell types as well as intestinal epithelial cells, and hepatocytes, it was not known whether this molecule is expressed by normal and/or UV exposed mouse skin cells, especially keratinocytes. To address this question, mouse skin from unirradiated and UVB-irradiated wild-type mice was fixed in formaline, sectioned and stained using an anti-mouse CD1d mAb (1H1) to detect CD<sub>1d</sub> protein. Detection of CD<sub>1d</sub> protein in normal unirradiated skin was negative (data not shown). However, CD1d protein was detected (brown color) in the epidermis and dermis of UVB-irradiated mouse skin (Fig. 5). Staining was largely confined to the more differentiated layers of the skin (stratum granulosum and stratum corneum) and at the cellular level was localized to the cytoplasm and nuclear membrane.

Thus, UVB-induced mouse skin damage/burning may be directly regulated at the level of the mouse keratinocyte rather than by antigen-presenting cells (locally or systemically).

#### CD1D GENE TRANSCRIPTION IS REGULATED BY UV RADIATION

Having demonstrated that UVB-induced skin damage is regulated by CD<sub>1d</sub> and that CD<sub>1d</sub> protein is expressed by mouse epidermal cells (keratinocytes), it was next important to establish whether skin CD1d expression is regulated by UV radiation. Any indication that skin CD1d expression is regulated by UV radiation would suggest that modulation of CD1d levels in skin is a critical factor responsible for regulating UV-induced skin damage. To address this question, the shaved dorsum of wild-type mice was exposed to a single dose (86mJ/cm<sup>2</sup>) of UVB radiation and at various times post irradiation (6, 24, 48, 72 and 96h) the irradiated skin was excised, RNA extracted and purified, and CD<sub>1d</sub> mRNA levels determined by semi-quantitative RT-PCR. As a control, normal non-irradiated mouse skin was excised, RNA extracted and purified and CD1d mRNA levels determined by semi-quantitative RT-PCR.

As shown in Fig. 6, the level of CD<sub>1d</sub> mRNA in whole mouse skin which decreased as early as 6h after UVB exposure was significantly reduced 24h post irradiation compared to levels detected in normal non-irradiated skin. In contrast, 48, 72 and 96 hours following UVB exposure CD1d mRNA levels were raised above the levels detected in normal unirradiated control skin. To further validate our studies on the effect of UVB radiation on skin CD1d gene transcription, we exposed the shaved dorsum of wild-type mice to varying doses of solar UV irradiation (UVB +UVA) - 1680 mJ/cm<sup>2</sup> (1 min), 16,800 mJ/cm<sup>2</sup> (10 min) or 33,600 mJ/cm<sup>2</sup> (20 min) of solar UV. At 6 and 72h post irradiation the irradiated skin was excised, RNA extracted and purified, and CD<sub>1d</sub> mRNA levels determined by semi-quantitative RT-PCR (Fig. 7). As with UVB exposure, we observed a similar decrease and increase in CD1d mRNA levels 6 and 72h following solar UV irradiation, respectively, regardless of the UV dose, suggesting that the response of skin CD<sub>1d</sub> gene transcription to UV radiation is an important event in the skin's response to the damaging effects of UV exposure.

#### HUMAN KERATINOCYTE CD1D GENE TRANSCRIPTION IS REGULATED BY SOLAR UV RADIATION

In an attempt to address whether human CD<sub>1d</sub> gene transcription is regulated by UV radiation we investigated whether cultured human keratinocytes exhibit a similar gene

transcription kinetic profile in response to UV irradiation. At different time points following exposure of triplicate DK7 cell keratinocyte cultures to a single dose of 5700mJ/cm<sup>2</sup> solar UV radiation, the cells were harvested for RNA and semi-quantitative RT-PCR performed to determine the relative level of CD1d mRNA (Fig. 8). As observed with UV irradiated (UVB or solar) mouse skin, CD1d mRNA levels decreased 6h post- irradiation compared to normal non-irradiated controls. Analysis of CD1d mRNA levels 10h post-irradiation revealed that these levels had further decreased compared to the levels detected in normal non-irradiated cell cultures. Between 16 and 48h hours after UV exposure, the level of CD1d mRNA increased proportionally; a pattern also observed in the skin of UV-irradiated whole wild-type skin suggesting that UV-induced CD1d gene transcription in mouse skin was likely being regulated at the level of the keratinocyte.

Human keratinocyte CD1d gene transcription is responsive to UV radiation and appears to be regulated in a similar manner to mouse skin CD1d implying that a) skin CD1d plays a critical role in regulating the response of skin to UV irradiation and b) modulation of CD1d levels in skin is a critical factor responsible for regulating UV-induced skin inflammation/damage.

#### GENE TRANSCRIPTION OF KEY GENES WHICH REGULATE SKIN INFLAMMATION IS DIMINISHED IN UVB IRRADIATED CD1d KNOCKOUT MOUSE SKIN

To further validate CD1d as a critical molecule responsible for regulating UVB-induced skin inflammation/damage we next investigated whether COX-2 and TNF- $\alpha$  gene transcription (key genes responsible for regulating UVB-induced skin inflammation/damage) is deregulated in UV-irradiated CD1d knockout mouse skin. It was found that COX-2 and TNF- $\alpha$  mRNA levels in CD1d knockout mouse skin were inhibited 48 and 72h after UV irradiation (Fig. 9). Since UV-induced skin damage/inflammation in wild-type mice is observed at 48 and 72h after UV exposure these data demonstrate that skin CD1d mediates UV-induced skin inflammation/damage by inducing COX-2 and TNF- $\alpha$  gene transcription.

#### Example 11

Inflammatory cytokines synthesis in UV-irradiated skin of CD1d Knockout mice is decreased compared to wild-type control mice.



### UV irradiation of mice

The mice were exposed once to an incident dose of 200 mJ/cm<sup>2</sup> UVB radiation. Three month old female inbred 129/C57BL/6 WT and 129/C57BL/6 CD1d KO mice were involved in this study (n=4).

### 5 Cytokine quantification

8 mm punch biopsies of skin were harvested at 0h, 24h, 48h, 72h, 96h and 168h post-irradiation and immediately frozen in liquid nitrogen. IL-6 and MIP1- alpha were quantified in skin homogenates using classical ELISA methods.

10 In WT mice UV-B irradiation induces a high up-regulation of inflammatory cytokines synthesis, 48 hours post-irradiation, whereas in CD<sub>1d</sub> KO mice synthesis of IL-6 and MIP1-alpha protein is significantly reduced. This demonstrates a major role for CD<sub>1d</sub> in UVB-induced cutaneous inflammation.

### Example 12

Hydrocortisone down-regulates chemical stress-induced CD<sub>1d</sub> gene transcription.

15 Primary human keratinocytes were grown in complete KGM before being exposed to 300μM H<sub>2</sub>O<sub>2</sub> as a stress factor. 48 hours after seeding, KGM medium was replaced by KGM without hydrocortisone and cultures were treated with 300 μM of H<sub>2</sub>O<sub>2</sub>. Total RNA was extracted at different time after treatment and CD<sub>1d</sub> mRNA quantified by Real Time PCR.

20 For Taq Man Assays, Applied Biosystems recommends to use 10 to 100ng of initial RNA quantity per well. Consequently, first strand cDNA synthesis was performed in a 20μl volume using 1μg of total RNA and 150μg of random hexamers following the manufacturer's recommendations (Superscript<sup>TM</sup> First-Strand Synthesis System for RT-PCR, 11904-018, Invitrogen). 1μl of the resulting cDNA samples was used for amplification by Real Time PCR.

25 The sets of primers and probes used for detection of CD1d cDNA were provided by Applied Biosystems as Assays on Demand (respectively Hs00174321\_m1 and Hs00166289\_m1). The primers and probes for the housekeeping gene GAPDH were provided as PDARS (4310884E, Applied Biosystems).

30 All the cDNA samples were tested in triplicate. PCR reaction mixtures were prepared on ice in micro centrifuge tubes. For one replicate, a pre-mix of 24μl was made using 1.25μl of 20X Target or Control mix, 10.25μl of water and 12.5μl of 2X TaqMan Universal Master Mix, and

added to 1µl of cDNA. The PCR reaction mixtures were gently and quickly centrifuged before being aliquoted at the rate of 25µl per well of a 96-wells plate. The plate was sealed, centrifuged at 2000rpm for 30 seconds and placed in a 5700 Sequence Detection System for thermal cycling and fluorescence analysis using the following PCR program:

- 2min at 50°C
- 10min at 95°C
- 40 cycles of 15 sec at 95°C and 1 min at 60°C

Results were analyzed using the GeneAmp® 5700 SDS software. Amplification plots showing amplification of cDNA of interest in function of the number of cycles were obtained.

The gene expression fold changes obtained in the test condition compared to the control condition were determined by the comparative Ct method using the following formula:

$$\text{Fold changes} = 2^{-\Delta\Delta C_t} = 2^{-(\Delta C_t \text{ test} - \Delta C_t \text{ control})}$$

$$\text{where } \Delta C_t = C_{t \text{ target gene}} - C_{t \text{ housekeeping gene}}$$

As shown in Fig. 11, modulation of CD<sub>1d</sub> gene expression is observed over time when cells are exposed to H<sub>2</sub>O<sub>2</sub>. In presence of Hydrocortisone, the pattern of CD<sub>1d</sub> gene expression obtained following H<sub>2</sub>O<sub>2</sub> challenge differed in that hydrocortisone suppressed CD<sub>1d</sub> transcription.

Thus, Hydrocortisone is able to down-regulate CD<sub>1d</sub> expression in cells subjected to a stress.

### **Example 13**

Phospholipid levels are disregulated in the skin and the intestine of CD<sub>1d</sub> knockout mice compared to wild-type skin.

Mice: Female inbred C57BL/6 CD1d<sup>-/-</sup> and wild-type C57BL/6 mice aged 5 months were sacrificed and the respective tissue excised. The pieces of skin/intestinal tissue from each mouse were snap frozen using liquid nitrogen. They were then analysed for lipid content.

The main family of lipids regulated by CD1d in skin were phospholipids.

		nMolar per gram of skin tissue	
		CD1d -/-*	Wild-type
5	Spingomyelin	33 +/- 30.4	176 +/- 116
	Lysophosphatidylcholine	3.8 +/- 3.7	10.0 +/- 4.1
10	Phoshatidylcholine	35.1 +/-21.1	8.5 +/- 12.9
	Phosphatidylserine	67 +/- 30.4	115 +/- 33
15			

\*The values are statistically significantly different from wild-type control ( $p < 0.05$ )

### **Sphingomyelin**


It is a ubiquitous component of animal cell membranes, where it is by far the most abundant sphingolipid. Indeed, it can comprise as much as 50% of the lipids in certain tissues, though it is usually less abundant than phosphatidylcholine. For example, it makes up about 10% of the lipids of brain. It is the single most abundant lipid in erythrocytes of most ruminant animals, where it replaces phosphatidylcholine entirely. In this instance, there is known to be a highly active phospholipase A that breaks down the glycerophospholipids, but not sphingomyelin. Like phosphatidylcholine, sphingomyelin tends to be most abundant in the plasma membrane, and especially in the outer leaflet, of cells.

Now, it is known that sphingomyelin (and other sphingolipids) and cholesterol may be located together in specific sub-domains (**'rafts'** or related structures termed 'caveolae') of membranes. As sphingolipids containing long, largely saturated acyl chains, they pack more tightly together, thus giving sphingolipids much higher melting temperatures than membrane glycerophospholipids. This tight acyl chain packing is **essential for raft lipid organization**, since the differential packing facility of sphingolipids and phospholipids is believed to lead to phase separation in the membrane, giving rise to sphingolipid-rich rafts ('liquid-ordered' phase) surrounded by glycerophospholipid-rich domains ('liquid-disordered' phase). Interactions

between specific cellular proteins and lipids in these rafts are believed to be important in signalling mechanisms implicating an important role for sphingomyelin in regulating cell signaling.

**Sphingomyelin is a key lipid in signal transduction processes involved in apoptosis.**

Also, sphingomyelin serves as a precursor for ceramides, long-chain bases and sphingosine-1-phosphate, as part of the 'sphingomyelin cycle', and many other important sphingolipids. (see figure below). Some of these have functions as intracellular messengers, and others are essential membrane constituents



### Lysophosphatidylcholine

- a phospholipid that is pro-inflammatory
- elevated in lesional psoriasis
- intracutaneous injection induces skin inflammation
- formed by the action of **phospholipaseA2** which is the rate limiting step in the production of arachadonic acid. ([link to regulation of COX-2 by CD<sub>1d</sub>](#)).

For the large intestine the following results were obtained:

			Large Intestine	
			nMoles per gram of Tissue	
Lipid Class	Saturation	Fatty Acid Family	CD1d-/-*	Wild-type
Cardiolipin	Saturated	Stearic Acid	405 ± 89	950 ± 442
		Total	405	950
	Unsaturated	Vaccenic Acid	74 ± 21	167 ± 45
		Oleic Acid	216 ± 42	377 ± 86
		α Linolenic Acid	23 ± 9	43 ± 9
		DHA	164 ± 92	596 ± 278
		Linoleic Acid	781 ± 210	2066 ± 727
		DGLA	36 ± 12	60 ± 16
		Total	1294	3309
Total Cardiolipin			1699	4259
Lysophosphatidylcholine	Saturated	Myristic Acid	78 ± 41	27 ± 5
		Arachidic Acid	7 ± 3	3 ± 0.5
		Total	85	30
	Unsaturated	Eicosenoic Acid	9 ± 5	3 ± 2
		Erucic Acid	234 ± 143	17 ± 36
		Eicosadienoic Acid	153 ± 98	30 ± 61
		DGLA	11 ± 5	4 ± 1
		Docosadienoic Acid	12 ± 8	2 ± 3
		Total	419	56
Total Lysophosphatidylcholine			504	86
Free Fatty Acids	Saturated	Pentadecanoic acid	31 ± 10	17 ± 5
		Total	31	17
	Unsaturated	Nervonic acid	9 ± 5	2 ± 4
		Total	9	2
Total Free Fatty Acids			40	19
Cholesterol Ester	Unsaturated	Eicosapentaenoic acid	5 ± 3	1 ± 3
		Palmitelaidic acid	49 ± 27	13 ± 8
		Total	54	14
Diglyceride	Unsaturated	Eicosenoic acid	11 ± 8	33 ± 16
		Total	11	33
Phosphatidylcholine	Unsaturated	Linoleic acid	2551 ± 2321	6398 ± 2862
		Total	2551	6398
Phosphatidylserine	Unsaturated	Linoleic acid	501 ± 105	1102 ± 338
		Total	501	1102

\* All values were statistically significantly different from wild-type groups (p < 0.05)

For the small intestine the following results were obtained:

			Small Intestine	
			nMoles per gram of Tissue	
Lipid Class	Saturation	Fatty Acid Family	CD1d-/-*	Wild-type
Cardiolipin	Unsaturated	Eicosenoic acid	12 ± 7	21 ± 3
		DHA	178 ± 124	480 ± 121
		Total	190	501
Phosphatidylcholine	Saturated	Behenic acid	13 ± 10	27 ± 10
		Total	13	27
	Unsaturated	Mead acid	7 ± 4	15 ± 4
		Eicosatetraenoic acid	2 ± 3	7 ± 3
		DGLA	154 ± 96	310 ± 115
		Docosadienoic acid	5 ± 4	10 ± 3
		Total	168	342
		Total Phosphatidylcholine	181	369

\* All values were statistically significantly different from wild-type groups (p< 0.05)

This above data support a role for CD<sub>1d</sub> in the regulation of phospholipid metabolism which controls inflammatory processes.

It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

Summary**ABSTRACT**

5 The present invention pertains to a method for preventing and/or treating epithelial tissue damage, such as is effected by inflammatory reactions, ageing or cancer and/or to prevent and/or treat hair loss. In particular, the present invention relates to substances and/or compositions modifying, in particular blocking endogenous CD<sub>1d</sub> function. According to another aspect the present invention also provides a method for screening for compounds suitable for use in the method and the composition of the present invention.

This listing of claims will replace all prior versions, and listing of claims in the application:

**Listing of claims:**

5 Claim 1 (currently amended) A substance capable ~~to~~ of blocking ~~block~~ or ~~modify~~ modifying endogenous CD<sub>1d</sub> function, selected from the group consisting of:

a polynucleotide antisense to a sequence comprised by the CD<sub>1d</sub>-gene and or CD<sub>1d</sub>-mRNA;

a polynucleotide antisense to a sequence comprised by the glucosylceramide synthase gene and/or the glucosylceramide synthase mRNA;

10 a polynucleotide sense to a sequence comprised by the sphingomyelinase or ceramide synthase gene and/or the sphingomyelinase or ceramide synthase mRNA;

a polypeptide or peptide, which is not an antibody, binding to CD<sub>1d</sub> and essentially blocking or modifying CD<sub>1d</sub> function; and

15 a lipid, which is selected from the group consisting of a sterol, fatty acid, glyceride and ~~or~~ phosphatidylinositol phosphate.

Claim 2 (currently amended) The substance according to claim 1, which is a compound reducing at least one of the transcription and/~~or~~ translation of the CD<sub>1d</sub> gene.

20 Claim 3 (currently amended) The substance according to claim 1 ~~and 2~~ which is derived from a source chosen from the group consisting of plants, microbes, ~~or~~ animals, ~~or~~ ingredients of green tea and ~~or~~ carotenoid.

25 Claim 4 (currently amended) The substance according to claim 1, which is a ligand of a receptor belonging to the TNF super-family, ~~in particular CD95/APO-1/Fas.~~

30 Claim 5 (currently amended) A method ~~The substance according to any of the preceding claims~~ for the preparation of a carrier for the prevention and/or treatment of the detrimental effects of stress to epithelial cells and/or hair loss comprising the steps of using a substance capable of blocking or modifying CD<sub>1d</sub> function selected from the group consisting of:



a polynucleotide antisense to a sequence comprised by the CD<sub>1d</sub>-gene and or CD<sub>1d</sub>-mRNA;

a polynucleotide antisense to a sequence comprised by the glucosylceramide synthase gene and/or the glucosylceramide synthase mRNA;

5 a polynucleotide sense to a sequence comprised by the sphingomyelinase or ceramide synthase gene and/or the sphingomyelinase or ceramide synthase mRNA;

a polypeptide or peptide, which is not an antibody, binding to CD<sub>1d</sub> and essentially blocking or modifying CD<sub>1d</sub> function; and

10 a lipid, which is selected from the group consisting of a sterol, fatty acid, glyceride and phosphatidylinositol phosphate.

Claim 6 (currently amended) A composition, containing a substance capable of blocking or modifying endogenous CD<sub>1d</sub> function selected from the group consisting of:

15 a polynucleotide antisense to a sequence comprised by the CD<sub>1d</sub>-gene and or CD<sub>1d</sub>-mRNA;

a polynucleotide antisense to a sequence comprised by the glucosylceramide synthase gene and/or the glucosylceramide synthase mRNA;

a polynucleotide sense to a sequence comprised by the sphingomyelinase or ceramide synthase gene and/or the sphingomyelinase or ceramide synthase mRNA;

20 a polypeptide or peptide, which is not an antibody, binding to CD<sub>1d</sub> and essentially blocking or modifying CD<sub>1d</sub> function; and

a lipid, which is selected from the group consisting of a sterol, fatty acid, glyceride and phosphatidylinositol phosphate ~~at least a substance according to any of the preceding claims.~~

25 Claim 7 (currently amended) The A composition according to claim 6, which is in a form selected from the group consisting of a food composition, a cosmetic composition ~~or~~ and a pharmaceutical composition.

30 Claim 8 (currently amended) The composition according to claim 6-7, which is in a form selected from the group consisting of milk, yogurt, curd, cheese, fermented milks, milk based

fermented products, ice-creams, milk based powders, infant formulae, cereal products, fermented cereal based products, mineral water, chocolate, ~~or~~ pet food, ~~or~~ lotions, shampoos, creams, sun-screens, after-sun creams, anti-ageing creams, ~~and/or~~ ointments, ~~or~~ tablets, liquid, dried oral supplement, wet oral supplement, dry tube-feeding, ~~or~~ wet tube-feeding ~~or~~ and an anti-cancer drug.

Claim 9 (currently amended) ~~A method Use of a substance according to the claims 1 to 5 or a composition according to any of the claims 6 to 8 for the prevention and/or treatment of damages~~ damage in epithelial tissues produced by a stress situation ~~and/or for the prevention and/or treatment of hair loss~~ comprising the step of administering to an individual a therapeutically-effective amount of a composition comprising a substance capable of blocking or modifying endogenous CD<sub>1d</sub> function selected from the group consisting of:

a polynucleotide antisense to a sequence comprised by the CD<sub>1d</sub>-gene and or CD<sub>1d</sub>-mRNA;

a polynucleotide antisense to a sequence comprised by the glucosylceramide synthase gene and/or the glucosylceramide synthase mRNA;

a polynucleotide sense to a sequence comprised by the sphingomyelinase or ceramide synthase gene and/or the sphingomyelinase or ceramide synthase mRNA;

a polypeptide or peptide, which is not an antibody, binding to CD<sub>1d</sub> and essentially blocking or modifying CD<sub>1d</sub> function; and

a lipid, which is selected from the group consisting of a sterol, fatty acid, glyceride and phosphatidylinositol phosphate.

Claim 10 (currently amended) ~~The method use of a substance or of a composition according to claim 9 for preventing and/or treatment of damages in epithelial tissues by a stress situation, wherein the lipid is a phytochemical, especially a natural or synthetic polyphenol, a ginkgolide or vitamin.~~

Claim 11 (currently amended) The method use according to claim 9, wherein the stress; situation is selected from the group consisting of a chemical stress, a biological stress ~~or~~ and a physical stress.

5 Claim 12 (currently amended) The method use according to ~~any of the claims claim~~ 11, wherein the ~~chemical~~ stress is exerted by a situation selected from the group consisting of exposure to oxidants or carcinogens, ~~or wherein the biological stress is exerted by~~ exposure to bacteria, viruses, fungi, lipids derived from surrounding cells ~~and/or~~ microbes, or ~~wherein the physical stress is exerted by~~ exposure to UV-irradiation.

10 Claim 13 (currently amended) The method use according to ~~any of the claims claim~~ 9 to 12, wherein the damage is selected from the group consisting of skin burning, ~~and/or~~ blistering, cataract formation, epidermal hyperplasia, cancer, inflammation, immune suppression, and skin ageing.

15 Claim 14 (currently amended) The method use according to ~~any of the claims claim~~ 9 to 13, wherein the epithelial cells are derived from a location selected from the group consisting of the skin, gut, eye, lung, prostate, liver, breast, kidney ~~and/or~~ the uterus.

20 Claim 15 (currently amended) The method use according to claim 13 14, wherein the cancer is selected from the group consisting of breast cancer, colon cancer, prostate cancer, liver cancer, pancreatic cancer, kidney cancer, non-melanoma and melanoma skin cancers.

25 Claim 16 (currently amended) A method for identifying CD<sub>1d</sub> blocking or modifying substances, ~~which comprises the following steps~~ comprising the steps of:

- (a) exposing epithelial cells to a substance of interest,
- (b) subjecting the epithelial cells to a stress situation,
- (c) determining the effect of said stress to said epithelial cells by screening for at least one one or more of the following assays assay selected from the group consisting of,

- 30 (i) epithelial hyperplasia (H&E),

- (ii) epithelial proliferation (BrUd, PCNA),
- (iii) epithelial apoptosis (TUNEL),
- (iv) p53 mutation accumulation,
- (v) quantitative and qualitative assessment of epithelial lipids,
- 5 (vi) co-clustering patterns of apoptotic and non-apoptotic cell surface receptors,
- (vii) production of pro-inflammatory cytokines,
- (viii) production of immuno-modulatory cytokines,
- (ix) markers of inflammation,
- 10 (x) anti-apoptotic transcription factors,
- (xi) markers of ageing,
- (d) comparing the results obtained with a control.

Claim 17 (currently amended) The method according to claim 16, wherein the  
15 stress situation is selected from the group consisting of a chemical stress, a biological stress ~~or~~  
and a physical stress.

Claim 18 (currently amended) The method according to claim 17, wherein the  
20 ~~chemical~~ stress is exerted by a situation selected from the group consisting of exposure to  
oxidants or carcinogens, ~~or wherein the biological stress is exerted by~~ exposure to bacteria,  
viruses, fungi, lipids derived from surrounding cells and/or microbes, and ~~or wherein the~~  
~~physical stress is exerted~~ by exposure to UV-irradiation.

Claim 19 (currently amended) The method according to claim 16 ~~to 18~~, wherein  
25 the pro-inflammatory cytokines are selected from the group consisting of IL-1, TNF- $\alpha$ , PGE-2,  
IL-6, IFN- $\gamma$  and ~~or~~ IL-8.

Claim 20 (currently amended) The method according to ~~any of the claims claim 16~~  
~~to 18~~, wherein the immuno-modulatory cytokines are selected from the group consisting of PAF,  
30 IL-10, IL-4 or TGF- $\beta$ .

Claim 21 (currently amended)      The method according to ~~any of the claims~~ claim 16 to 18, wherein the lipids are selected from the group consisting of phospholipids, sphingolipids and glycosphingolipids.

5      Claim 22 (currently amended)      The method according to ~~any of the claims~~ claim 16 to 18, wherein the markers of inflammation include Cox-2 and iNos.

Claim 23 (currently amended)      The method according to ~~any of the claims~~ claim 16 to 18, wherein the anti-apoptotic transcription factors include AP-1 and NFkappaB.

10

Claim 24 (currently amended)      The method according to ~~any of the claims~~ claim 16 to 18, wherein the markers of aging include elastases, collagenases, metalloproteinases, gelatinases, stromelysins, and telomerases.

15      Claim 25 (currently amended)      A method Use of a substance according to any of the claims 1 to 5 or a composition according to any of the claims 6 to 8 for decreasing multi-drug resistance of cancers comprising the steps of administering to an individual taking a cancer drug a therapeutically-effective amount of a composition capable of blocking or modifying endogenous CD<sub>1d</sub> function selected from the group consisting of:

20      a polynucleotide antisense to a sequence comprised by the CD<sub>1d</sub>-gene and or CD<sub>1d</sub>-mRNA;

a polynucleotide antisense to a sequence comprised by the glucosylceramide synthase gene and/or the glucosylceramide synthase mRNA;

25      a polynucleotide sense to a sequence comprised by the sphingomyelinase or ceramide synthase gene and/or the sphingomyelinase or ceramide synthase mRNA;

a polypeptide or peptide, which is not an antibody, binding to CD<sub>1d</sub> and essentially blocking or modifying CD<sub>1d</sub> function; and

a lipid, which is selected from the group consisting of a sterol, fatty acid, glyceride and phosphatidylinositol phosphate.

Claim 26 (currently amended)      The method use according to claim 25, wherein the individual has a cancer selected from the group consisting of is skin, gut or and breast cancer.

5      Claim 27 (currently amended)      A method of screening comprising the steps Use of  
using cells expressing and/or over-expressing CD<sub>1d</sub> in an assay for screening for substances  
modifying and/or blocking CD<sub>1d</sub> function.

10      Claim 28 (currently amended)      A method of determining activity of substances  
comprising the steps of using Use of CD<sub>1d</sub><sup>-/-</sup> animals as a test model for determining the activity  
of substances influencing damages in epithelial tissues produced by a stress situation and/or hair  
loss.

15      Claim 29 (currently amended)      A method of providing Use of a substance  
according to any of the claims 1 to 5 in gene therapy comprising the step of using a substance  
capable of blocking or modifying endogenous CD<sub>1d</sub> function selected from the group consisting  
of:

a polynucleotide antisense to a sequence comprised by the CD<sub>1d</sub>-gene and or CD<sub>1d</sub>-  
mRNA;

20      a polynucleotide antisense to a sequence comprised by the glucosylceramide synthase  
gene and/or the glucosylceramide synthase mRNA;

a polynucleotide sense to a sequence comprised by the sphingomyelinase or ceramide  
synthase gene and/or the sphingomyelinase or ceramide synthase mRNA;

a polypeptide or peptide, which is not an antibody, binding to CD<sub>1d</sub> and essentially  
blocking or modifying CD<sub>1d</sub> function; and

25      a lipid, which is selected from the group consisting of a sterol, fatty acid, glyceride and  
phosphatidylinositol phosphate in a gene therapy method.

Claim 30 (new)      The substance according to claim 1, which is a ligand of a receptor  
belonging to CD95/APO-1/Fas.

Claim 31 (new) A method for the prevention and/or treatment of hair loss comprising the step of administering to an individual a therapeutically-effective amount of a substance capable of blocking or modifying endogenous CD<sub>1d</sub> function selected from the group consisting of:

5 a polynucleotide antisense to a sequence comprised by the CD<sub>1d</sub>-gene and or CD<sub>1d</sub>-mRNA;

a polynucleotide antisense to a sequence comprised by the glucosylceramide synthase gene and/or the glucosylceramide synthase mRNA;

10 a polynucleotide sense to a sequence comprised by the sphingomyelinase or ceramide synthase gene and/or the sphingomyelinase or ceramide synthase mRNA;

a polypeptide or peptide, which is not an antibody, binding to CD<sub>1d</sub> and essentially blocking or modifying CD<sub>1d</sub> function; and

a lipid, which is selected from the group consisting of a sterol, fatty acid, glyceride and phosphatidylinositol phosphate.

15

Claim 32 (new) The method according to claim 9, wherein the lipid is selected from the group consisting of a natural or synthetic polyphenol, a ginkgolide and vitamin.

## REMARKS

Pursuant to this Preliminary Amendment, Claims 1-29 have been amended, newly-submitted Claims 30-32 have been added, and amendments have been made to the specification. This Preliminary Amendment does not add new subject matter. Moreover, Applicants note for  
5 the record that the Preliminary Amendment is submitted to place the above-identified application in proper U.S. format and not to avoid prior art. Therefore, Applicants do not intend to disclaim any subject matter in view of the Preliminary Amendment.

Respectfully submitted,  
BELL, BOYD & LLOYD LLC

10  
BY 

15  
Robert M. Barrett  
Reg. No. 30,142  
P.O. Box 1135  
Chicago, Illinois 60690-1135  
Phone: (312) 807-4204

Dated: February 22, 2005



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**